Spectrum of somatic mutations in tumors arising in different large bowel locations in patients with hereditary predisposition to colorectal cancer by Manuela Cristina Dias Pinheiro
  
Manuela Cristina Dias Pinheiro 
 
 
Espectro de mutações somáticas em tumores com origem em locais 
diferentes do intestino grosso em doentes com predisposição 
hereditária para cancro colo-rectal 
 
 
 
 
 
Tese de Candidatura ao grau de Doutor em 
Ciências Biomédicas submetida ao Instituto de 
Ciências Biomédicas Abel Salazar da Universidade 
do Porto. 
 
Orientador – Doutor Manuel R. Teixeira 
Categoria – Professor Catedrático Convidado 
Afiliação – Instituto de Ciências Biomédicas Abel 
Salazar da Universidade do Porto.  
 
 

  
Manuela Cristina Dias Pinheiro 
 
 
Spectrum of somatic mutations in tumors arising in different large 
bowel locations in patients with hereditary predisposition to 
colorectal cancer 
 
 
 
 
 
Dissertation for applying to a Doctoral degree in 
Biomedical Sciences submitted to the Institute of 
Biomedical Sciences Abel Salazar of the University 
of Porto. 
 
Supervisor – Doutor Manuel R. Teixeira 
Affiliation – Institute of Biomedical Sciences Abel 
Salazar of the University of Porto.  
Host Institution - Department of Genetics, 
Portuguese Oncology Institute of Porto.  
 
 
 

ACKNOWLEDGEMENTS 
 
To Professor Manuel Teixeira, Director of the Genetics Department and Research 
Centre of IPO-Porto, who has guided this thesis, for the immeasurable support, 
availability and understanding demonstrated during its execution. 
 
To Professor Rui Henrique and Drª Paula Lopes, from de IPO-Porto Anatomy 
Pathology Department, for the willingness collaboration concerning tumor sample 
collection and immunohistochemistry analysis, essential for the development of this 
thesis.  
 
To Professor Fátima Carneiro and Professor Karl Heinimann for the willingness 
collaboration regarding Hospital de S. João and Basel University tumor sample 
collection, respectively and to Professor Raquel Seruca for the scientific support.  
 
To all co-authors of this work which contributed to the output of this thesis. 
 
To Fundação para a Ciência e a Tecnologia (FCT) who supported this thesis by a 
research grant (SFRH/BD/65326/2009). 
  
To all the colleagues of the Genetics Department, especially from the hereditary 
genetics group, for the support and friendly environment during the execution of this 
thesis. 
 
To all my friends, but especially to Anita, Carla, Clara, Catarina, Maria José, Pedro e 
Susana, for all the support, comprehension and cheerfulness moments. 
 
Finally, I thank my family, especially my parents for their patience and unconditional 
support. 
 
 

TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS............................................................................................ 5 
TABLE OF CONTENTS .............................................................................................. 7 
SUMMARY .................................................................................................................. 9 
RESUMO................................................................................................................... 11 
LIST OF PUBLICATIONS.......................................................................................... 13 
LIST OF ABBREVIATIONS ....................................................................................... 15 
INTRODUCTION ....................................................................................................... 19 
1 - Anatomy and embryology of the large bowel .............................................. 19 
2 - Colorectal cancer incidence and mortality rates ......................................... 20 
3 - Colorectal cancer risk factors ....................................................................... 22 
4 - Colorectal cancer diagnosis and staging ..................................................... 23 
5 - Colorectal cancer treatment .......................................................................... 25 
6 - Colorectal carcinogenesis ............................................................................. 25 
6.1 - Chromosomal instability pathway.............................................................. 26 
6.2 - Microsatellite instability pathway ............................................................... 28 
6.3 - CpG island methylation pathway ............................................................... 31 
7 - Lynch syndrome ............................................................................................. 33 
7.1 - Lynch syndrome characterization.............................................................. 33 
7.2 - MMR germline mutational spectrum .......................................................... 34 
7.3 - Lynch syndrome CRC somatic alterations ................................................ 36 
AIMS ......................................................................................................................... 39 
PAPER I .................................................................................................................... 41 
PAPER II ................................................................................................................... 51 
PAPER III .................................................................................................................. 61 
GENERAL DISCUSSION .......................................................................................... 95 
1 - Identification of a novel exonic rearrangement affecting MLH1 and the 
contiguous LRRFIP2 that is a founder mutation in Portuguese Lynch 
syndrome families ............................................................................................... 95 
 
2 - Identification of a MSH2 founder mutation in Portuguese Lynch syndrome 
families but recurrent worldwide ........................................................................ 97 
3 - Target gene mutational spectrum in Lynch syndrome CRC according to 
MMR germline mutation ...................................................................................... 98 
4 - Target gene mutational spectrum in Lynch syndrome CRC according to 
large bowel location .......................................................................................... 100 
CONCLUSIONS ...................................................................................................... 103 
FUTURE PERSPECTIVES ..................................................................................... 105 
REFERENCES ........................................................................................................ 107 
  
SUMMARY 
Lynch syndrome is an autosomal dominant disorder characterized by a high 
incidence of early-onset colorectal cancer (CRC) and extracolonic tumors of the 
endometrium, stomach, small bowel, ureter, renal pelvis, ovary, and hepatobiliary 
tract, accounting for up to 4% of all CRC. This syndrome is commonly caused by a 
genetic defect affecting one of the four mismatch repair genes MLH1, MSH2, MSH6 
and PMS2. The germline mutational spectrum of Lynch syndrome is highly 
heterogeneous, but specific mutations are observed at high frequencies in well-
defined populations or ethnic groups, because of founder and/or recurrent effects. 
The identification of founder and/or recurrent mutations facilitates the molecular 
diagnosis of Lynch syndrome by making cost-effective mutational analysis of specific 
gene regions before full screening of all MMR genes. 
More than 95% of the tumors arising in carriers of MMR gene mutations 
present microsatellite instability (MSI), due to MMR deficiency. Through the MSI 
pathway, colorectal cancer progression is accelerated by a rapid mutation 
accumulation in coding repetitive sequences of target genes with growth-related, 
apoptosis and DNA repair functions. We have previously reported in sporadic MSI 
CRC that the target genes in MMR deficient tumors in distal colon and rectum differ 
from those occurring elsewhere in the colon. This study aimed to ascertain the 
relative contribution of the underlying molecular defect driving carcinogenesis, on one 
hand, and the site of tumor origin, on the other, for the pattern of acquired genetic 
changes in CRC from patients with Lynch syndrome.  
To determine if two frequent mutations in Lynch syndrome families, one of 
them novel and the other described worldwide, are founder and/or recurrent 
mutations, we performed haplotype analyses in Portuguese Lynch syndrome families. 
In order to characterize the spectrum of somatic mutations in CRC from patients with 
Lynch syndrome, we analyzed a series of CRC for microsatellite instability in genes 
predicted to be selective target genes of MSI and known to be involved in several 
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 pathways of colorectal carcinogenesis, especially the TGFβ superfamily and WNT 
pathways.  
Our results indicate that the novel exonic rearrangement MLH1 
c.1896+279_oLRRFIP2:c.1750-678del and the point mutation MSH2 c.388_389del 
mutation are two frequent Portuguese founder mutations, the latter being a recurrent 
mutation worldwide. The high frequency of these two founder mutations in our Lynch 
syndrome families indicates that screening for these two mutations as a first step may 
increase the cost-effectiveness of genetic testing of Lynch syndrome suspects of 
Portuguese ancestry, especially those originating from the north of Portugal. 
Regarding the somatic mutational spectrum of Lynch syndrome CRC, we 
detected a high frequency of mutations in genes belonging to the TGFβ superfamily 
signaling pathways. We also observed that CRC from Lynch syndrome patients with 
germline mutations in MLH1 or MSH2 present a significantly higher frequency of 
target gene mutations when compared to patients with germline MSH6 mutations. A 
higher mean frequency of mutations in other genes with microsatellite sequences was 
also observed in CRC with somatic mutations in MSH3 and/or MSH6 when compared 
to CRC without somatic mutations in these two MMR genes. Finally, mutations in 
microsatellite sequences (A)7 of BMPR2 and (A)8 of MSH3 genes were significantly 
more frequent in CRC with origin in distal colon in Lynch syndrome patients. To 
conclude, the pattern of somatic genetic changes differs in colorectal carcinomas 
depending on the large bowel site of origin and between Lynch syndrome and 
sporadic MSI CRC, suggesting that carcinogenesis can occur by different pathways 
even if driven by generalized MSI.  
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 RESUMO 
A síndrome de Lynch é uma doença autossómica dominante caracterizada por 
uma elevada incidência de carcinoma colo-rectal (CCR) e ocorrência de outras 
neoplasias, nomeadamente no endométrio, estômago, intestino delgado, uréter, 
bacinete, ovário e tracto hepatobiliar, representando até cerca de 4% de todos os 
CCR. Alterações nos genes MMR estão na origem desta síndrome, nomeadamente 
nos genes MLH1, MSH2, MSH6 e PMS2. O espectro mutacional da síndrome de 
Lynch é muito heterogéneo, mas mutações específicas são observadas com 
elevadas frequências em populações bem definidas ou grupos étnicos devido a 
efeitos fundadores e/ou recorrentes. A identificação de mutações fundadoras e/ou 
recorrentes facilita o diagnóstico molecular da síndrome de Lynch porque direcciona 
a pesquisa de mutações para regiões específicas antes da análise total dos genes 
MMR. 
Mais de 95% dos tumores em portadores de mutações nos genes MMR 
apresentam instabilidade de microssatélites (IMS). Na via de carcinogénese da IMS a 
progressão do CCR é acelerada pela rápida acumulação de mutações em 
sequências repetitivas de genes alvo com funções relacionadas com o crescimento 
celular, apoptose e reparação de DNA. O nosso grupo reportou num trabalho anterior 
em CCR esporádico com IMS que os genes alvo da via da IMS são diferentes entre 
tumores com origem no cólon distal e proximal. Este estudo teve como objectivo 
avaliar a contribuição relativa da alteração molecular germinativa, por um lado, e o 
local de origem do tumor, pelo outro, no padrão de alterações genéticas em CCR de 
doentes com síndrome de Lynch.  
De forma a determinar se duas mutações muito frequentes em famílias 
portuguesas com síndrome de Lynch, sendo que uma delas é nova e a outra está 
descrita em vários países, são mutações fundadoras e/ou recorrentes, efectuámos 
estudos de haplótipos. Com o intuito de caracterizar o espectro de mutações 
somáticas em CCR de doentes com síndrome de Lynch, avaliamos a IMS em 
potenciais e supostos genes alvo relevantes nas vias envolvidas na carcinogénese 
colo-rectal, particularmente as vias do TGFβ e WNT.  
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 Os nossos resultados indicam que o rearranjo exónico MLH1 
c.1896+279_oLRRFIP2:c.1750-678del e a mutação pontual MSH2 c.388_389del são 
duas mutações fundadoras Portuguesas, sendo que a última também é recorrente a 
nível mundial. A elevada frequência destas duas mutações justifica que a sua 
pesquisa seja efectuada antes da análise completa dos genes MMR, o que poderá 
traduzir-se num aumento da relação custo-benefício no diagnóstico genético de 
síndrome de Lynch de famílias portuguesas, especialmente nas famílias originárias 
do norte de Portugal. 
 Relativamente ao espectro mutacional dos CCR de doentes com síndrome de 
Lynch, foi detectada uma elevada frequência de mutações nos genes da via de 
sinalização do TGFβ. Também observámos que CRC de doentes com mutações 
germinativas nos genes MLH1 ou MSH2 apresentavam maior frequência média de 
mutações nos genes alvo quando comparado com os doentes com mutação 
germinativa no gene MSH6, sendo esta diferença significativa. Adicionalmente, 
também foi detetada uma maior frequência média de mutações nos genes alvo em 
CRC que apresentavam mutações somáticas nos genes MSH3 e/ou MSH6 quando 
comparado com os casos sem alterações somáticas nestes genes. Finalmente, 
mutações nas sequências microssatélites (A)7 do gene BMPR2 e (A)8 do gene 
MSH3 foram significativamente mais frequentes em CCR com origem no cólon distal. 
Em conclusão, o padrão de mutações somáticas em CCR é diferente consoante o 
local de origem do tumor e entre CCR de doentes com síndrome de Lynch e CCR 
esporádico com IMS, sugerindo que a carcinogénese colo-rectal associada à IMS 
pode ocorrer por diferentes vias mesmo quando é impulsionada por IMS 
generalizada. 
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INTRODUCTION 
INTRODUCTION 
 
1 - Anatomy and embryology of the large bowel  
The large bowel constitutes a tube of variable diameter with approximately 120 
to 150 cm in length and can be divided in cecum, ascending colon, transverse, 
descending colon sigmoid and rectum (Figure 1). The cecum is a capacious saclike 
segment localized in the proximal colon, with an average diameter of 7.5 cm and 
length of 10 cm. The ascending colon, approximately 15 to 20 cm in length, runs 
upward toward the liver on the right side. The transverse colon is approximately 30 to 
60 cm in length and is located between the hepatic and splenic flexures. The 
descending colon extends downward from the splenic flexure for approximately 20 to 
25 cm, followed by the sigmoid colon that varies in length from 15 to 50 cm. The 
rectum, which is 10 to 15 cm in length, ends in the proximal border of the anal 
sphincter complex (Petras et al, 2008; Fry et al, 2012). Usually, the different 
segments of the large bowel are classified as proximal or distal depending if they are 
located proximally or distally to the splenic flexure. The segments from cecum to 
transverse colon are considered proximal colon and from descending colon to rectum 
as distal colon (Petras et al, 2008). Regarding the anatomic blood supply, the 
proximal colon is supplied by the superior mesenteric artery and distal colon by the 
inferior mesenteric artery. The parasympathetic supply to the proximal colon comes 
from the right vagus nerve, whereas distal colon receives sympathetic supply from the 
preganglionic lumbar splanchnics of L1 to L3 and the lower rectum receives from the 
postganglionic sacral splanchnics of S2 to S4 (Petras et al, 2008; Fry et al, 2012). 
The primitive gut tube has its origin in the endodermal roof of the yolk sac and 
at the beginning of the third week of development, being divided into three regions: 
the foregut, the midgut and the hindgut. Foregut-derived structures end at the second 
portion of the duodenum, the midgut gives origin from the duodenal ampulla to the 
distal transverse colon, and the hindgut from the distal third of the transverse colon to 
the rectum. The primitive distal rectum presents a specialized area denominated 
19 
 
INTRODUCTION 
cloaca, composed of endoderm and ectoderm derived tissues (Junqueira and Zago, 
1997; Fry et al, 2012). 
 
 
Figure 1 - Anatomy of the large bowel (adapted from Marieb et al, 2008). 
 
The major functions of the large bowel are nutrient and water absorption and 
fecal storage, occurring differentially in the various segments of the large bowel. 
Nutrient and water absorption take place mostly in the cecum and decreases towards 
the rectum, and the sigmoid and the rectum serves as a fecal reservoir. Structural 
and physiological differences of the segments that constitute the large bowel, as well 
as the mucosal capillary density and width and the bacterial flora, explain this 
functional heterogeneity (Bresalier, 2010; Fry et al, 2012).  
 
2 - Colorectal cancer incidence and mortality rates 
The frequency of colorectal cancer (CRC) varies widely among different 
populations, presenting the highest incidence rates in Europe, North America, and 
Oceania and the lowest in Africa and South America (Ferlay et al, 2013). In 2012, 
CRC was the fourth most incident malignancy, preceded by breast, prostate and lung 
cancers, accounting for 9.7% (1 360 602 cases) of all new cancer cases diagnosed in 
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the world, with an estimated age-standardized rate (ASR) incidence of 17.2/100 000 
(Ferlay et al, 2013). CRC accounted for 8.5% (693 881 deaths) of all deaths from 
cancer, being the fourth most common, preceded by lung, liver and stomach cancers, 
with an estimated ASR mortality of 8.4/100 000. Regarding gender, CRC was the 
third most common cancer in men and the second in women, with an estimated ASR 
incidence of 20.6/100 000 and 14.3/100 000, respectively (Ferlay et al, 2013). CRC 
represents the fourth most common cause of death from cancer in men and the third 
in women, with an estimated ASR mortality of 10.0/100 000 and 6.9/100 000, 
respectively (Ferlay et al, 2013). 
 
A      B  
Figure 2 - Incidence and mortality age standardized rates (ASR) in men (A) and women (B) in Portugal 
in 2012 (Ferlay et al, 2013). 
 
In Portugal, in 2012, CRC accounted for 14.5% (7129 cases) of all new cancer 
cases, being the third most incident malignancy with an estimated ASR incidence of 
31.7/100 000 preceded by breast and prostate cancer (Ferlay et al, 2013). CRC was 
the second most common cause of death from cancer (3797 deaths) preceded only 
by lung cancer, accounting for 15.7% of all deaths from cancer with an estimated 
ASR mortality of 13.6/100 000. Considering gender, CRC was the second most 
common cancer in men and women, preceded only by prostate and breast cancer, 
with an estimated ASR incidence of 41.8/100 000 and 23.6/100 000, respectively 
21 
 
INTRODUCTION 
(Ferlay et al, 2013). Regarding mortality CRC, was the second most common cause 
of death in men and women with an estimated ASR mortality of 19.0/100 000 and 
9.4/100 000, preceded only by lung and breast cancer, respectively (Figure 2) (Ferlay 
et al, 2013). 
 
3 - Colorectal cancer risk factors 
The risk of developing CRC depends on a number of factors involving an 
interaction between genetic and environmental causes. Age is the most common risk 
factor, increasing from the fourth to the eighth decade of life (Haggar and Boushey, 
2009). A personal history of CRC or adenoma and chronic inflammatory bowel 
disease (such as ulcerative colitis and Crohn's disease) are also significant risk 
factors (Eaden et al, 2001; Dyson and Rutter, 2012; Levi et al, 2012; Martinez et al, 
2012; Beaugerie et al, 2013).  
Individuals with a family history of CRC also present an increased risk of 
developing the disease, especially if the index case is diagnosed before 45 years of 
age (Hemminki and Chen, 2004; Taylor et al, 2010; Cirillo et al, 2013). It is estimated 
that about 10% of CRC cases are hereditary, occurring predominantly in the context 
of Lynch syndrome (also designated Hereditary Non-Polyposis Colorectal Cancer, 
HNPCC), Familial Adenomatous Polyposis (FAP), MUTYH-associated polyposis 
(MAP), and the hamartomatous polyposis syndromes (Peutz-Jeghers syndrome, 
juvenile polyposis, and Cowden disease) (Lynch et al, 1993; Al-Tassan et al, 2002; 
Gammon et al, 2009; Half et al, 2009; Bogaert and Prenen, 2014).  
Several studies have shown that migrant populations tend to acquire the 
relative risk of developing CRC of their adopted countries. Furthermore, inter-regional 
differences in incidence of CRC, including differences among population groups living 
in geographic proximity but with different lifestyles, strongly suggest that 
environmental factors play an important role in the etiology of this disease (Center et 
al, 2009; Durko and Malecka-Panas, 2014). Several studies have demonstrated that 
consumption of high amounts of fat, red and processed meat and low intake of fiber, 
fruits, vegetables, and whole grains might be associated with the development of 
CRC (van Duijnhoven et al, 2009; Chan e al, 2011). Additionally, has been described 
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an association between obesity, tobacco and excessive alcohol consumption and the 
risk of developing CRC (Dai et al, 2007; Paskett et al, 2007; Bongaerts et al, 2008). 
On the other hand, physical, occupational or recreational, activity appears to lessen 
the risk of this cancer, probably due to its effect on intestinal transit, bile acid 
metabolism and immune system (Chao et al, 2004; Wei et al, 2004).  
 
4 - Colorectal cancer diagnosis and staging  
CRC screening depends on the risk of the individual. In the general population 
routine CRC screening should begin at age 50; however, individuals presenting an 
increased risk due to a personal or family history of CRC or adenomas, inflammatory 
bowel disease, or a hereditary CRC syndrome require a more personalized 
screening. CRC screening can be performed by endoscopic, radiologic imaging and 
stool/fecal-based exams, being colonoscopy the most complete procedure allowing 
examination of the entire large bowel and simultaneous removal of polyps for 
histologic analysis (Levin et al, 2008; Czito and Willett, 2012; NCCN, 2013).  
Although CRC patients often present minimal or no symptoms, these can 
include rectal bleeding, bowel dysfunction as constipation or diarrhea, abdominal 
discomfort, weight loss, fatigue and anemia. The symptoms can differ according to 
large bowel tumor location. Cancers of the proximal colon are commonly associated 
with iron-deficiency anemia due to occult blood loss, whereas distal colon cancers are 
often accompanied by obstruction and rectal bleeding (Hamilton and Sharp, 2004; 
Astin et al, 2011; Czito and Willett, 2012).   
Accurate CRC histology and staging, including differentiation, lymphatic 
invasion, and extension of tumor free surgical resection margins, is imperative for the 
determination of diagnosis, therapy and prognosis. The majority (>90%) of large 
bowel tumors are adenocarcinomas, but can include other histologic types as 
squamous cell carcinomas, carcinoids, leiomyosarcomas, gastrointestinal stromal 
tumors and lymphomas (Bosman  et al. 2010). The standard CRC staging system is 
the tumor, node, and metastasis (TNM) staging system of the American Joint 
Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) 
(Table 1). The grading system for colorectal adenocarcinomas is based on 
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architectural and cytologic features, but the degree of gland formation is widely 
considered the most important feature and generally it is classified in grade 1 (well 
differentiated), grade 2 (moderately differentiated) and grade 3 (poorly differentiated). 
Subsite CRC localization analysis in some populations indicates that 
approximately 60% of them occur in the distal colon, with 30% to 35% occurring in the 
rectum, 20% to 25% in sigmoid, 3% to 5% in descending colon, 7% to 15% in 
transverse colon and 25% to 26% in ascending colon (including cecum) (Bresalier 
2010; Larsen and Bray, 2010; Cancer Research UK, 2014) 
 
Table 1 - American Joint Committee on Cancer. Tumor, Node, Metastasis (TNM) staging 
system for colorectal cancer (2009).  
Primary Tumor (T)  
TX  Primary tumor cannot be assessed  
T0  No evidence of primary tumor  
Tis  Carcinoma in situ: intraepithelial or invasion of lamina propria  
T1  Tumor invades submucosa  
T2  Tumor invades muscularis propria  
T3  Tumor invades through the muscularis propria into pericolic tissues  
T4a  Tumor penetrates to the surface of the visceral peritoneum 
T4b  Tumor is adherent to or directly invades other organs or structures 
Regional Lymph Nodes (N)  
NX  Regional lymph nodes cannot be assessed  
N0  No regional lymph node metastasis  
N1  Metastasis in one to three regional lymph nodes  
N1a  Metastasis in one regional lymph node  
N1b  Metastasis in two to three regional lymph nodes  
N1c  
Tumor deposit(s) in the subserosa, mesentery, or nonperitonealized pericolic 
or perirectal tissues without regional nodal metastasis  
N2  Metastasis in four or more regional lymph nodes  
N2a  Metastasis in four to six regional lymph nodes  
N2b  Metastasis in seven or more regional lymph nodes  
Distant Metastasis (M)  
MX  Distant metastasis cannot be assessed.  
M0  No distant metastasis  
M1  Distant metastasis  
M1a  
Metastasis confined to one organ or site (e.g., liver, lung, ovary, nonregional 
node)  
M1b  Metastases in more than one organ/site or the peritoneum  
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5 - Colorectal cancer treatment 
 The mainstay therapy for locoregional colon and rectal carcinoma is surgery. 
In colon cancer, adjuvant chemotherapy is administered to reduce the risk of 
recurrence and, according to National Comprehensive Cancer Network (NCCN) 
guidelines, 5-Fluorouracil (5-FU) regimens in combination with leucovorin or 
oxaliplatin (FOLFOX) is the current choice for stage III and high-risk stage II patients. 
In rectal cancer, neoadjuvant combined-modality therapy, including chemotherapy 
and radiation, is administered to improve resectability, sphincter preservation, and 
reduce local as well as distant recurrence. Postoperative oxaliplatin-containing 
regimens such as FOLFOX are typically used in the setting of rectal cancer 
postoperatively. In the setting of metastatic CRC, combination of 5-FU chemotherapy 
regimens with an inhibitor of vascular endothelial growth factor (VEGF), such as 
Bevacizumab, or an inhibitor of epidermal growth factor receptor (EGFR), such as 
Cetuximab or Panitumumab, is the treatment of choice. EGFR inhibitors should only 
be used in patients that present KRAS/NRAS wild-type tumors. 
 
6 - Colorectal carcinogenesis 
In 1990, Fearon and Vogelstein described a multistep genetic model that 
consisted in the accumulation of genetic mutations in multiple genes that regulate cell 
growth and differentiation, by which colon cancers were believed to progress through 
an adenoma-carcinoma sequence (Fearon and Vogelstein, 1990). According to this 
model, CRC arises as a result of mutational activation of oncogenes combined with 
mutational inactivation of tumor suppressor genes, and the accumulation of genetic 
alterations, rather than their order, is the responsible for the biological behavior of the 
cancer. This linear model has evolved to a more complex, comprehensive, and 
mechanistic approach designated as the chromosomal instability (CIN) pathway. 
Since then, at least two other major distinct molecular pathways have been 
recognized, the microsatellite instability (MSI) and the CpG island methylator 
phenotype (CIMP) pathways (Ionov et al, 1993; Toyota et al, 1999).  
In the progression from adenoma to carcinoma, tumors following the MSI and 
CIN pathways often display mutations in either APC or CTNNB1 (β-catenin) and in 
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KRAS in the early stages of colorectal carcinogenesis, diverging their genetic and 
epigenetic profiles more significantly towards malignancy (Ilyas et al, 1999; Miyaki et 
al, 1999; Jass et al, 2003; Huang et al, 2004). Furthermore, although the subsequent 
gene targets may be different, mutations frequently affect the same pathways. 
Several signaling pathways implicated in cell cycle control, such as TGFβ, MAPK, 
WNT and AKT, are affected in most CRC. For instance, the TGFβ signaling pathway, 
involved in cell proliferation inhibition, can be compromised in the MSI and CIN 
pathways through TGFBR2 and SMAD gene alterations, respectively (Miyaki et al, 
1999; Roth et al, 2000; Shin et al, 2000).  
 
6.1 - Chromosomal instability pathway 
CIN is the most common cause of genomic instability in CRC, accounting for 
70-85% of sporadic CRC. This pathway is characterized by the occurrence of 
aneuploidy, chromosomal genomic amplifications, and a high frequency of loss of 
heterozigosity (LOH). Chromosomal structural alterations occurs more frequently in 
chromosomes 1, 5, 8, 17, and 18, presenting frequently loss of the long arm of 
chromosome 5 (5q) and 18 (18q) and the short arm of chromosome 17 (17p). 
Mutations in oncogenes and tumor suppressor genes (e.g. APC, KRAS, TP53) 
essential for colorectal carcinogenesis are also observed at a high frequency (Smith 
et al, 2002; Lüchtenborg et al, 2005; Camps et al, 2006; Diep et al, 2006).  
APC is a tumor suppressor gene located in 5q21 that is mutated in the 
germline in the CRC hereditary syndrome FAP (Nishisho et al, 1991). The most well 
documented function of APC is in the canonical Wingless-Type MMTV Integration 
Site Family (WNT) signaling pathway (Morin et al, 1997). APC induces degradation of 
β-catenin, functioning as a negative regulator of the WNT, pathway controlling cell 
growth, differentiation and apoptosis. APC constitutes with AXIN and GSK-3β a 
multiprotein complex that bounds to β-catenin and causes its phosphorylation, 
subsequent ubiquitination, and destruction in the proteosome. The disruption of this 
complex leads to the accumulation in the cytoplasm of a stabilized, free β-catenin that 
can translocate to the nucleus and lead to the transcription of genes involved in cell 
cycle regulation (Saito-Diaz et al, 2013). In CRC, one of the main causes of disruption 
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of this multiprotein complex is mutation of the APC gene, which is an early event in 
colorectal carcinogenesis with frequencies of 30 to 70% in sporadic colorectal 
adenomas and 34% to 80% in sporadic CRC (Miyoshi et al, 1992; Powell et al, 1992; 
Yashima et al, 1994; Rowan et al, 2000; Diergaarde et al, 2003; Lüchtenborg et al, 
2004). In sporadic CRC cases with wild-type APC gene, APC gene promoter 
hypermethylation or CTNNB1 point mutation have been described to explain the 
sustained activation of the WNT signaling pathway (Sparks et al, 1998; Thorstensen 
et al, 2005; Sameer et al, 2011).  
KRAS is a proto-oncogene located at 12p12.1 that encodes a GTP-binding 
protein. When it is bound to GTP, the ras protein is active and becomes inactive by 
hydrolysis of GTP to GDP. Mutations in this gene result in a complex less sensitive to 
hydrolysis, keeping the ras protein in a constitutively active state. This will lead to cell 
proliferation through a variety of signaling pathways, including the mitogen-activated 
protein kinases (MAPK) pathway (Maruta et al, 1994; Guerrero et al, 2000). The 
frequency of mutations in the KRAS proto-oncogene in sporadic CRC is 30 to 50% 
(Smith et al, 2002; Calistri et al, 2005; Berg et al, 2010).  
18q deletion, encompassing the SMAD2 and SMAD4 genes, has been 
reported in up to 70% of CRC (Miyaki et al, 1999; Woodford-Richens, 2001). SMAD 
proteins mediate the TGFβ signaling pathway, which regulates cell growth and 
apoptosis (Zawel et al, 1998; Zhou et al, 1998; Kouvidou, 2006). About 20% of CRCs 
have been found to present SMAD4 mutations, which occur at a later stage of 
colorectal carcinogenesis and are an indicator of advanced phenotypes (Miyaki et al, 
1999; Woodford-Richens, 2001).  
TP53 is a tumor suppressor gene located on the short arm of chromosome 17 
(17p13.1) that regulates cell cycle and is involved in apoptosis and DNA repair (Isobe, 
1986). The protein encoded by this gene is a key transcription factor that mediates 
cell cycle arrest in order to facilitate DNA repair during replication or induces 
apoptosis if the repair is not possible (Green and Kroemer, 2009). TP53 loss, usually 
by 17p deletion, is described as a late event in the CIN pathway, being associated 
with the adenoma to carcinoma transition. This fact is supported by the observed 
increase in alterations frequency, either by mutation or by LOH, with the histological 
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stage of the lesion, namely 4 to 14% in adenoma and 27 to 61% in CRC (De 
Benedetti et al, 1993; Ohue et al, 1994; Hardingham et al, 1998; Smith et al, 2002; 
Aissi et al, 2014; Vasovcak et al, 2014). 
Although recent studies indicate that simultaneous alterations in these genes is 
not as frequent as initially believed and different molecular patterns have been 
observed in CRC, that develop through the CIN pathway, mutations in APC, KRAS 
and TP53 genes are essential events in colorectal carcinogenesis and this model of 
carcinogenesis remains a paradigm (Smith et al, 2002; Calistri et al, 2005). 
 
6.2 - Microsatellite instability pathway 
Another important pathway that leads to genomic instability is the MSI pathway 
that is operative in 15% to 20% of sporadic CRC and in as up to 96% of Lynch 
syndrome CRC (Lothe et al, 1993; Thibodeau et al, 1993; Aaltonen et al, 1994; 
Bocker et al, 1996, Caldés et al, 2004; Mead et al, 2007). Microsatellites are short, 
repetitive nucleotide sequences consisting of 1 to 6 bases per repeat unit that are 
distributed throughout the human genome. These sequences are more prone to 
errors during DNA replication due to their repetitive structure (Farber et al, 1994; 
Arzimanoglou et al, 1998). The DNA mismatch repair (MMR) system function is to 
recognize and repair base-pair mismatches that occur during DNA replication and 
that have escaped the proofreading process, increasing the replication fidelity 100 to 
1000-fold. Microsatellite instability is a reflection of the inability of the MMR system to 
correct these errors (Koi et al, 1994; Umar et al, 1997). 
 The MMR system is a multi-protein complex composed by MSH2, MSH6 and 
MSH3 (human MutS homologs (MSH) of Escherichia coli), MLH1 and MLH3 (human 
MutL homologs (MLH) of Escherichia coli) and PMS2 (post-meiotic segregation MutL 
homolog of Escherichia coli). These proteins contain heterodimeric interaction 
domains, ATP binding/hydrolysis domains and protein–protein interaction domains. 
When DNA structural integrity is compromised, the first step of eukaryotic mismatch 
repair is error recognition by MSH2 and heterodimer formation with either MSH3 or 
MSH6, depending on the nature of the irregularity. MSH3 is specific for 
insertion/deletion loops of 2 to 4 nucleotides, while MSH6 is specific for single 
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nucleotide loops or mismatches. The next step is the recruitment of the MLH family 
proteins, namely MLH1 and PMS2, by the ATP-bound MSH heterodimer. The 
multiprotein complex will displace the main processive DNA polymerase and the 
sliding clamp PCNA, and recruit base excision machinery to remove the tract in which 
the mismatch occurred. The final step is resynthesis of the excision gap by the 
replicative DNA polymerase using the remaining DNA strand as a template (Figure 3) 
(Peltomaki, 2001a, 2001b; Marti et al, 2002). Germline mutations in one of the MMR 
genes, namely in tumors from patients with Lynch syndrome, or epigenetic alterations 
such as MLH1 promoter hypermethylation in sporadic CRC, are the most common 
cause of MSI (Cunningham et al, 1998; Forster et al, 1998; Herman et al, 1998; 
Kuismanen et al, 2000; Wheeler et al, 2000).  
 
 
Figure 3 - Steps involved in mismatch repair during DNA replication. Different types of mismatches, 
single base mismatches or insertion/deletion of 2 to 4 bases, are recognized by MSH2-MSH6 
heterodimer or MSH2-MSH3 heterodimer, respectively. A sliding clamp is created around the DNA, 
requiring the exchange of ATP for ADP. This complex is then bound by heterodimers of MLH1 with 
PMS2 or PMS1 or MLH3. Excision of the mismatch occurs when the DNA MMR protein sliding clamp 
interacts with exonuclease-1, PCNA, and DNA polymerase. The strand containing the mismatch is 
excised and resynthesis occurs with correction of the error (adapted from Sinicrope and Sargeant, 
2012). 
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Sporadic MSI CRC tends to be diploid and present lower frequency of LOH 
and mutations in APC, KRAS and TP53 genes (Olschwang et al, 1997; Forster et al, 
1998; Salahshor et al, 1999; Jass et al, 2003; Jones et al, 2005). Contrarily, 
mutations in the BRAF gene have been identified in sporadic CRC with MSI 
associated with hypermethylation of the MLH1 promoter gene (Wang et al, 2003; 
Domingo et al, 2004). All point mutations occur within the kinase domain of BRAF, the 
most frequent being the p.Val600Glu mutation, leading to the constitutive activation of 
Braf kinase (Davies, 2002; Wang et al, 2003). BRAF is a proto-oncogene member of 
the RAF family of serine/threonine kinases and is an immediate downstream effector 
of RAS in the RAS/RAF/MAPK pathway. BRAF mutation is almost mutually exclusive 
with KRAS mutations (Domingo et al, 2004; Koinuma et al, 2004). 
   Furthermore, through the MSI pathway, colorectal cancer progression is 
accelerated by a rapid mutation accumulation in coding repetitive sequences of target 
genes with growth-related functions (Malkhosyan et al, 1996; Perucho, 1996). These 
frameshift mutations will lead to the inactivation of the function of these genes, giving 
them a potential role in colorectal carcinogenesis (Iacopetta et al, 1998; Woerner et 
al, 2001; Samowitz et al, 2002). There is a large list of genes containing coding 
repeats that are susceptible to mutations in the presence of a defective MMR system. 
For example, genes involved in DNA repair (e.g. MSH3, MSH6 and MLH3), apoptosis 
(e.g. BAX, BCL10, and CASP5), signal transduction (e.g. TGFBR2, ACVR2A, IGF2R) 
and cell cycle regulation (PTEN and PRDM2). Inactivation of the TGFβ signaling 
pathway appears to play a key role in MSI CRC development, resulting in 
uncontrolled cellular proliferation and dysregulation of cell death mechanisms 
(Derynck et al, 2001; Elliott et al, 2005). The TGFβ superfamily of proteins includes 
three TGF-β isoforms, the bone morphogenetic proteins (BMP), inhibins and activins. 
In MSI CRC, the most frequent mutated members of this pathway are TGFBR2 (70 to 
90%) and ACVR2A (83% to 85%), occurring frequently in concomitance (Iacopetta et 
al, 1998; Schwartz et al, 1999; Calin et al, 2000; Jung et al, 2004; Fernández-Peralta 
et al, 2005; Jung et al, 2006; Ogino et al, 2007; Shima et al, 2011). Genes with a role 
in apoptosis are also frequently mutated in MSI CRC. The pro-apoptotic tumor 
suppressor gene BAX is the canonical example, presenting mutations in 30 to 66 % 
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of MSI CRC (Schwartz et al, 1999; Calin et al, 2000; Samowitz et al, 2002; Potočnik 
et al, 2003; Fernández-Peralta et al, 2005; Jung et al, 2006; Shima et al, 2011). 
These frameshift mutations will lead to loss of function of BAX, promoting cell escape 
from intrinsic apoptosis mechanisms. Somatic mutations in microsatellite sequences 
within MSH3 and MSH6 have also been described in sporadic MSI CRC with 
frequencies ranging from 20 to 46% and 17.5% to 40%, respectively (Malkhosyan et 
al, 1996; Schwartz et al, 1999; Duval et al, 1999; Orimo et al, 1999; Calin et al, 2000). 
These mutations have been considered as secondary events and MSH3 and MSH6 
as “secondary mutators” in a "mutator that mutates another mutator" model, given 
that they are DNA repair proteins prone to frameshift mutations themselves; when 
mutated somatically the MSI phenotype is exacerbated (Orimo et al, 1999).  
Sporadic MSI CRC present a number of characteristic clinicopathologic 
features. CRC tend to be located more proximally in the colon, be poorly 
differentiated and of the mucinous histology type, display extensive lymphocytic 
infiltration and present a better overall survival compared with microsatellite stable 
tumors (Senba et al, 1998; Samowitz et al, 2001; Smyrk et al, 2001; Gervaz et al, 
2002).  
 
6.3 - CpG island methylation pathway  
The observation of a widespread CpG island methylation in CRC lead to the 
discovery of a third pathway, designated the CpG Island Methylation Pathway (CIMP) 
(Toyota et al, 1999). Methylation of gene promoter region results in gene silencing, 
providing an alternative mechanism for loss of function of tumor suppressor genes. 
The CIMP pathway is present in approximately 20% of patients with CRC. Genes 
implicated in colorectal carcinogenesis that can be silenced by hypermethylation 
include APC, MGMT and the classical example of the hypermethylation silencing of 
MLH1, which occurs in >80% of sporadic MSI CRC (Wheeler et al, 2000; Arnold et al, 
2004). Five markers have been indicated to serve as markers for CIMP, CACNA1G, 
IGF2, NEUROG1, RUNX3, and SOCS1 and CIMP positivity is defined by methylation 
of at least three markers (Weisenberger et al, 2006). It has been suggested that 
CIMP positive tumors can be divided in two types, CIMP high related to BRAF 
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mutations and MLH1 promoter hypermethylation and CIMP low related to KRAS 
mutations (Kambara et al, 2004; Shen et al, 2007; Curtin et al, 2011).  
CIMP CRC usually develops through an alternative route of colorectal cancer 
carcinogenesis denominated the serrated pathway in which the precursor lesions are 
sessile serrated adenomas (Kambara et al, 2004). CIMP CRC tumors present 
particular clinicopathological features, although some of them overlap with the ones 
observed in MSI CRC, such as an association with proximal colon location and poor 
differentiation. Additionally, these patients usually are female and of more advanced 
age, with a history of cigarette smoking (Grady, 2007; Ogino, 2009).  
Several studies indicate that the three pathways, (CIN, MIN and CIMP) are not 
mutually exclusive, being possible that tumors can exhibit features of more than one 
or even follow yet uncharacterized pathways. CRC subtyping has been addressed by 
several authors regarding prognosis, biological, morphological and clinical features 
showing a clear evidence for the presence of CRC molecular subtypes (Kim et al, 
2013; Samadder et al, 2013). Accordingly to Jass (2007), using pathological, clinical 
and molecular features, CRC should be classified in to five molecular subtypes: CIMP 
high/MSI high (12% of CRC), with origin in serrated adenomas and characterized by 
BRAF mutation and MLH1 promoter hypermethylation; CIMP high/MSI low or 
microsatellite stable (8%), with origin in serrated adenomas and characterized by 
BRAF mutation and methylation of multiple genes; CIMP low/MSI low or microsatellite 
stable (20%), with origin in tubular, tubulovillus, or serrated adenomas and 
characterized by chromosomal instability (CIN), KRAS mutation, and MGMT 
methylation; CIMP negative/microsatellite stable (57%), which originates in traditional 
adenoma and is characterized by CIN; and Lynch syndrome, CIMP negative/MSI high 
and negative for BRAF mutations. According to this classification approximately 70% 
of CRC arise via a adenoma pathway and approximately 30% via a serrated pathway, 
characterized by activation of the MAPK pathway (KRAS or BRAF mutations, 
mutually exclusive), presence of CIMP (Low or High) and presenting or not MSI.  
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7 - Lynch syndrome 
 
7.1 - Lynch syndrome characterization 
The most common cause of hereditary predisposition to CRC is Lynch 
syndrome, accounting for up to 4% of all CRC (Aaltonen et al, 1998; Barnetson et al, 
2006; Hampel et al, 2008). Lynch syndrome is an autosomal dominant disorder 
characterized by a high incidence of early-onset (<50 years old) CRC and 
extracolonic tumors of the endometrium, stomach, small bowel, ureter, renal pelvis, 
ovary, and hepatobiliary tract (Lynch et al, 2003). The diagnostic criteria for identifying 
individuals with Lynch syndrome were established in 1991 in Amsterdam. These 
criteria, named Amsterdam I Criteria, stated the following: (1) three relatives with 
colorectal cancer, one being a first-degree relative of the other two; (2) two 
successive generations affected with colorectal cancer; (3) one family member who 
developed colorectal cancer before age 50 and (4) FAP must be excluded and all 
cancers verified pathologically (Vasen et al, 1999). However, these criteria 
underestimate Lynch syndrome in some families, so the Amsterdam II Criteria were 
developed in order to include extracolonic tumors with the goal of increasing 
sensitivity. However, although family history alone may be used to highlight high-risk 
families, several studies demonstrated that these criteria still remained too restrictive. 
A broader set of criteria known as the revised Bethesda guidelines were developed, 
combining histopathologic and/or genetic analysis with family history (Table 2) (Umar 
et al, 2004). Patients that meet only the Bethesda guidelines should first have their 
tumors assessed for MSI and/or MMR protein staining by immunohistochemistry 
(IHC). In order to discriminate between a hereditary or a sporadic event, tumors with 
immunohistochemical loss of MLH1 should be analyzed for MLH1 promoter 
hypermethylation and BRAF (p.Val600Glu hotspot mutation) (Wang et al, 2003; 
Domingo et al, 2004, 2005; Miyaki et al, 2004). 
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Table 2 - Amsterdam criteria II and Revised Bethesda guidelines (adapted from Vasen et al, 2007). 
Amsterdam criteria II 
1. At least three relatives with CRC or with a Lynch syndrome-associated cancer1, 
2. one relative should be a first-degree relative of the other two, 
3. two successive generations should be affected, 
4. one tumor should be diagnosed before the age of 50 years, 
5. FAP should be excluded in the CRC case if any, 
6. tumors should be verified by histopathological examination. 
Revised Bethesda guidelines 
1. CRC diagnosed in a patient aged <50 years. 
2. Presence of synchronous, metachronous colorectal or other Lynch syndrome-related tumors, regardless 
of age. 
3. CRC with MSI-H phenotype diagnosed in a patient aged <60 years. 
4. Patient with CRC and a first-degree relative with a Lynch syndrome-related tumor2, with one of the 
cancers diagnosed at age <50 years. 
5. Patient with CRC with two or more first-degree or second-degree relatives with a Lynch syndrome-related 
tumor regardless of age. 
1Lynch syndrome-associated cancer includesthose of endometrium, small bowel, ureter or renal pelvis. 
2Lynch syndrome-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter, renal pelvis, 
biliary tract and brain tumors, sebaceous gland adenomas and keratoacanthomas, and carcinoma of the small 
bowel. 
 
Lynch syndrome phenotypic features include early-onset colorectal cancer, 
synchronous or metachronous CRC, and a predominance of right-sided tumors. 
Additionally, the patients present a comparatively favorable prognosis and absence of 
distant organ metastasis, with CRC presenting dense lymphocytic infiltrates pointing 
to a possible protective effect by the immune system (Percesepe et al, 1997; Peel et 
al, 2000; Smyrk et al, 2001). 
 
7.2 - MMR germline mutational spectrum  
Lynch syndrome is caused mainly by mutations in the mismatch repair (MMR) 
genes MLH1, MSH2, MSH6 and PMS2 and, as indicated above, MMR mutation 
carriers present a substantially increased risk of colorectal and endometrial cancers, 
along with increased risk of ovarian, gastric, small bowel, urothelial, brain, 
hepatobiliary, pancreatic, bladder, kidney, prostate and breast cancer (Lynch et al, 
2003, Peltomäki et al, 2005).  
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Identification of the underlying germline mutation guides clinical management 
of Lynch syndrome families, with implications for presymptomatic surveillance and 
cancer treatment options. Molecular genetic heterogeneity must be considered when 
assessing the Lynch syndrome cancer phenotype. Current data suggest that families 
with MLH1 mutations have a higher expression of CRC, families with MSH2 
mutations present more extra-colonic cancers and families that harbor MSH6 
mutations develop CRC at a more advanced age and have a higher risk of developing 
endometrial cancers (Lin et al, 1998; Wagner et al, 2001; Koornstra et al, 2009). 
As of December 2012, according to the International Society for 
Gastrointestinal Hereditary Tumors (InSiGHT) database, of the 2,360 constitutional 
variants described 39% were in the MLH1, 36% in MSH2, 19% in MSH6 and 6% in 
PMS2 genes (Thompson et al, 2014). Recently, germline deletions in the EPCAM 
gene (a gene located directly upstream of MSH2), which encodes a epithelial cell 
adhesion molecule, has been identified as the causative mutation in some families 
with Lynch syndrome operating by epigenetic silencing MSH2 (Ligtenberg et al, 
2009). 
The mutational spectrum of MMR genes includes nonsense/frameshift variants 
predicted to cause protein truncation (34%), nonsynonymous variants (32%) including 
missense substitutions, small in-frame insertion-deletion mutations and read-through 
alterations of the translation termination codon, intronic variants (11%), splicing site 
alterations (7%), synonymous variants (5%), and ATG/UTR variants (2%) (Thompson 
et al, 2014). Large genomic rearrangements represent 9% of the reported variants, 
consisting of single or multi-exonic deletions or duplications, but its frequency among 
Lynch syndrome families can be as high as 20% in certain populations, mainly 
occurring in the MSH2 and MLH1 genes (Charbonnier  et al, 2002; Di Fiore et al, 
2004; Thompson et al, 2014). Three major mechanisms have been proposed for 
genomic rearrangements in the human genome: nonallelic homologous 
recombination (NAHR), non-homologous end-joining (NHEJ) and the fork stalling and 
template switching (FoSTeS) models (Gu et al, 2008; Chen et al, 2010). Molecular 
characterization of large rearrangement breakpoints demonstrated that the majority 
are caused by homologous recombination between Alu repeats. Alu repeats are short 
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interspersed elements whose transposition has been repeatedly implicated in genetic 
variability and heritable disorders, including Lynch syndrome and hereditary 
breast/ovarian cancer (Moisio et al, 1996; Peixoto et al, 2009). 
Although Lynch syndrome is characterized by marked genetic heterogeneity, 
considering the several types of mutations located throughout the four relevant MMR 
genes, the occurrence of recurrent and/or founder effects explain why some specific 
mutations are observed at high frequency in well-defined populations or ethnic 
groups. Founder mutations have been identified in Lynch families worldwide (Chan et 
al, 2001; Wagner et al, 2003; Caluseriu et al, 2004; Sun et al, 2005). For example, the 
Finnish founder mutation MLH1 exon 16 deletion with an age estimation of 400 to 
1075 years, accounts for more than 50% of all Lynch syndrome families in certain 
regions of Finland (Moisio et al, 1996). On the other hand, the MSH2 splice-site 
mutation c.942+3A>T, which was proven to be widespread in the Newfoundland 
population through a founder effect, has been observed in many other populations 
arising de novo, and therefore is considered a worldwide recurrent mutation with a 
founder effect in Newfoundland (Froggatt et al, 1999; Desai et al, 2000). This 
mutation apparently arises repeatedly de novo because the region where it occurs, a 
microsatellite sequence, is susceptible to slippage during DNA replication, accounting 
for 5 to 10% of all Lynch syndrome families worldwide (Desai et al, 2000; Hampel et 
al, 2005). The identification of founder and/or recurrent mutations facilitates the 
molecular diagnosis of Lynch syndrome by making cost-effective mutational analysis 
of specific gene regions before full screening of all MMR genes. 
 
7.3 - Lynch syndrome CRC somatic alterations 
More than 95% of CRC from Lynch syndrome patients present MSI, making it 
a dependable indicator of MMR deficiency and providing a straightforward, although 
indirect, approach to identify MMR mutation carriers (Aaltonen et al, 1994; Dietmaier 
et al, 1997). In 1997, the National Cancer Institute recommended a panel of 5 
microsatellite loci, including two mononucleotide (BAT25, BAT26) and three 
dinucleotide markers (D2S123, D5S346, and D17S250), to assess the MSI tumor 
status (Boland et al, 1998). Subsequently, other researchers proposed a panel with 
36 
 
INTRODUCTION 
five mononucleotide repeat markers (BAT25, BAT26, NR21, NR24, and NR27) that 
obviates the need for normal tissue for comparison and presents a higher sensitivity 
and specificity (Patil et al, 2012). Depending on the number of microsatellite markers 
displaying novel alleles, MSI can subsequently be classified as MSI-H (MSI-H, >2 out 
of 5 markers), MSI-L (MSI-L, 1 out of 5), or microsatellite stable (MSS, 0 out of 5) 
(Boland et al, 1998). The presence of MSI-H is normally associated with mutations in 
MLH1 and MSH2 genes and MSI-L appears to some extent due to mutations in the 
MSH6 gene (Peterlongo et al, 2003; Barnetson et al, 2006). Whether MSI-L CRC 
constitutes a separated group of tumors is still not clear: whereas some authors 
suggest that they do not present clear differences from MSS CRC, regarding clinical, 
biological, and morphological parameters, others defend that they constitute a 
separate group of tumors based in the observation of distinct molecular profiles when 
compared to MSI-H and MSS CRC (Whitehall et al, 2002; Yearsley et al, 2006). 
Although sporadic and Lynch syndrome MSI CRC share certain 
clinicopathologic and molecular characteristics, some studies indicate differences 
between these two groups. Lynch syndrome MSI CRC generally occur at a younger 
age and present more frequently lymphocytic infiltration and a mucinous histologic 
type (Young et al, 2001; Shia et al, 2003; Yearsley et al, 2006). Furthermore, even 
though the tumors tend to occur more frequently in the proximal colon, some authors 
have reported frequencies of to 40% of Lynch syndrome MSI CRC occurring in distal 
colon, contrasting with sporadic MSI CRC of which ~90% occur in the proximal colon 
(Kim et al, 1994; Mueller-Koch et al, 2005; Moghbeli et al 2011; Moussa et al, 2011). 
Significant differences in the spectrum of molecular alterations between MSI CRC 
occurring in Lynch syndrome and in sporadic CRC have also been observed. 
CTNNB1 gene mutations occur in MSI Lynch syndrome CRC but not in sporadic MSI 
CRC (Johnson et al, 2005). Inversely, BRAF mutations, namely p.Val600Glu, are 
associated with sporadic MSI CRC (Wang et al, 2003; Domingo et al, 2004, 2005). 
The differences in the molecular profiles of these two pathways are consistent with 
the differing carcinogenesis routes of hereditary versus sporadic MSI CRC, 
specifically the traditional adenoma-carcinoma sequence in the former and a serrated 
route in the latter. 
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In MSI CRC from patients with Lynch syndrome, similarly to sporadic MSI 
CRC, mutations have been described in coding microsatellite sequences of several 
genes with important cellular roles, such as growth factor receptors (TGFBR2 and 
IGF2R), genes involved in apoptosis (BAX), as well as genes relevant for DNA repair 
(MSH3 and MSH6) (Perucho, 1996; Boland et al, 1998; Yamamoto et al, 1998; Yagi 
et al, 1998; Fujiwara et al, 1998; Calin et al, 2000). However, differences between the 
MSI profiles in different types of Lynch syndrome associated cancers have been 
described, for instance between endometrial and colorectal cancers. This suggests 
that biological features and functional roles of target genes may differ depending on 
the tissue of tumor origin (Myeroff et al, 1995; Duval et al, 1999, Kuismanen et al, 
2002). Furthermore, differences have been reported between distal and proximal 
sporadic MSI CRC regarding target genes mutational spectrum (Pinheiro et al, 2010). 
In Lynch syndrome, there is virtually no data relating target gene mutation frequency 
or pattern with CRC large bowel location. 
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AIMS 
 
This study aimed to ascertain the relative contribution of the underlying 
molecular defect driving carcinogenesis, on one hand, and the site of tumor origin, on 
the other, for the pattern of acquired genetic changes in CRC from patients with 
Lynch syndrome. Specifically, the objectives of this thesis were: 
1. To perform haplotype analyses in Portuguese Lynch syndrome families 
presenting a frequent novel exonic rearrangement affecting MLH1 gene, in 
order to determine if this is a founder mutation.  
2. To perform haplotype analyses in Portuguese and worldwide Lynch syndrome 
families presenting the frequent MSH2 c.388_389del mutation, in order to 
determine if it is a founder and/or a recurrent mutation.  
3. To characterize and compare the spectrum of somatic mutations in selected 
target genes involved in colorectal carcinogenesis in CRC from patients with 
Lynch syndrome with different germline MMR mutations. 
4. To characterize and compare the pattern of somatic mutations and disrupted 
pathways in CRC arising in proximal and distal colon in Lynch syndrome 
patients.  
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ABSTRACT 
We have previously reported in sporadic MSI CRC that the target genes in 
MMR deficient tumors in distal colon and rectum differ from those occurring 
elsewhere in the colon. In this study we aimed to compare the target gene mutational 
pattern in MSI CRC from Lynch syndrome patients stratified by tumor location, 
germline mutated gene and type of mutation. A series of CRC from patients with 
Lynch syndrome was analyzed for microsatellite instability in genes predicted to be 
selective target genes of MSI and known to be involved in several pathways of 
colorectal carcinogenesis, especially the TGFβ superfamily and WNT pathways. The 
most frequently mutated genes belonged to the TGFβ superfamily signaling 
pathways, namely the  ACVR2A and TGFBR2 genes. A significantly higher frequency 
of target gene mutations was observed in CRC from patients with germline mutations 
in MLH1 or MSH2 when compared to patients with germline MSH6 mutations. 
Furthermore, CRC with somatic mutations in MSH3 and/or MSH6 presented a higher 
mean frequency of mutations in the other genes with microsatellite sequences when 
compared to CRC without somatic mutations in these two MMR genes. Finally, 
mutations in microsatellite sequences (A)7 of BMPR2 and (A)8 of MSH3 genes were 
significantly more frequent in distal CRC in Lynch syndrome patients. Our results 
indicate that the pattern of genetic changes differs in colorectal carcinomas 
depending on the large bowel site of origin and between Lynch syndrome and 
sporadic MSI CRC, suggesting that carcinogenesis can occur by different pathways 
even if driven by generalized MSI. 
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INTRODUCTION 
Lynch syndrome is a highly penetrant, autosomal dominant disease 
characterized by early-onset colorectal cancer (CRC) and extracolonic tumors of the 
endometrium, stomach, small bowel, ureter, renal pelvis, ovary, and hepatobiliary 
tract (Lynch et al, 2003). This is the most common hereditary CRC syndrome 
accounting for up to 4% of all CRC cases (Aaltonen et al, 1998; Hampel et al, 2008) 
and is commonly caused by a genetic defect affecting one of the four mismatch repair 
(MMR) genes MLH1, MSH2, MSH6 and PMS2 (Lagerstedt et al, 2007). The selection 
of families for genetic testing is mainly based on the personal and family cancer 
history using the Amsterdam criteria or the Bethesda guidelines (Vasen et al, 1999; 
Umar et al, 2004).  
Lynch syndrome-associated CRCs are usually associated with a variety of 
histologic features, including tumor-infiltrating lymphocytes, Crohn disease-like 
lymphocytic reaction, mucinous or signet ring differentiation and a medullary growth 
pattern. Furthermore, they occur predominantly in the proximal colon (up to 70%), 
even though a significant incidence of distal CRC is also described (Percesepe et al, 
1997; Peel et al, 2000; Smyrk et al, 2001). Multiple differences between cancer of the 
proximal and distal colon with regard to clinical behavior, epidemiological, 
pathological and molecular features suggest that the mechanisms of colorectal 
carcinogenesis may differ according to tumor location (Kapiteijn et al, 2001; Fernebro 
et al, 2002; Christie et al, 2013). A possible explanation for this could be the different 
embryological origin of the large bowel, as the ascending and two thirds of transverse 
colon originates from the midgut and the last third of transverse, descending colon 
and rectum from the hindgut (Junqueira and Zago, 1997). 
More than 95% of the tumors arising in carriers of MMR gene mutations 
present microsatellite instability (MSI) (Aaltonen et al, 1994; Dietmaier et al, 1997). 
MSI is characterized by a widespread instability in coding and noncoding 
microsatellite sequences, due to MMR deficiency (Perucho, 1996). Through the MSI 
pathway, colorectal cancer progression is accelerated by a rapid mutation 
accumulation in coding repetitive sequences of target genes with growth-related 
functions. In Lynch syndrome MSI CRC, mutations have been found in a number of 
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genes with key cellular roles, such as growth factor receptors (TGFBR2 and IGF2R), 
genes involved in apoptosis (BAX), as well as genes relevant for DNA repair (MSH3 
and MSH6) (Perucho, 1996; Fujiwara et al, 1998; Yagi et al, 1998; Calin et al, 2000), 
together with many other microsatellite mutations that are not mechanistically 
responsible for the behavior of tumor cells. 
We have previously reported in sporadic MSI CRC that the target genes in 
MMR deficient tumors in distal colon and rectum differ from those occurring 
elsewhere in the colon (Pinheiro et al, 2010). In this study, we aimed to compare the 
target genes mutational pattern in MSI CRC from Lynch syndrome patients stratified 
by tumor location, germline mutated gene and type of mutation (founder mutations 
compared to other mutations in the same gene). 
  
MATERIAL AND METHODS 
Patients, samples, and DNA extraction 
This study includes altogether 129 CRC from 114 patients belonging to 98 
Lynch syndrome families with deleterious MMR germline mutations (Table 1). The 
test series includes 78 CRC (two rectal tumors were excluded from our initial series 
because the patients had received neoadjuvant treatment), obtained by surgical 
resection, from 65 patients belonging to 50 Portuguese Lynch syndrome families 
presenting a germline MMR gene mutation. These mutations were identified by 
routine genetic diagnosis during the period of 1997 to 2011 at the Genetics 
Department of the Portuguese Oncology Institute, Porto, Portugal, after genetic 
counseling and informed consent. Thirty-nine families were followed at the 
Portuguese Oncology Institute and 11 at the S. João Hospital, Porto, Portugal. 
Twenty-eight of the families fulfilled the Amsterdam criteria, whereas the remaining 
presented the Bethesda criteria for genetic testing. Twenty-seven (55%) families 
presented a pathogenic germline mutation in MSH2, 16 (31%) in MLH1, six (12%) in 
MSH6 and one (2%) in PMS2 (data not shown) (Table 1). Furthermore, eight (16%) 
and ten (20%) of these families presented the MLH1 c.1896+280_oLRRFIP2:c.1750-
678del or the MSH2 c.388_389del Portuguese founder mutations, respectively 
(Pinheiro et al, 2011, 2013). Forty (51%) tumors belonged to patients presenting a 
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germline mutation in MSH2, 31 (40%) in MLH1, six (8%) in MSH6 and one (1%) in 
PMS2. The 65 patients included 33 females and 32 males with a mean CRC 
diagnosis age of 46 years (range, 15-75). Clinical data was drawn from hospital 
records and tumor staging was performed using the American Joint Committee on 
Cancer (AJCC) criteria. Summary clinic-pathological data is presented in Table 1. All 
the large bowel regions up to the splenic flexure were considered proximal colon and 
after that as distal colon. All tumor samples were paraffin embedded and were 
reviewed by a pathologist. Peripheral blood was collected from the same patients. 
DNA was isolated from paraffin-embedded tumor as described by Lungu et al (1992) 
and from peripheral blood using standard procedures. This study was approved by 
the Institutional Review Board.  
We analyzed an additional series that included 51 CRC samples from 49 
patients belonging to 48 Lynch syndrome families from Basel, Switzerland. Twenty-
six (54%) families presented germline mutations in MLH1, 21 (4%) in MSH2 and 1 
(2%) in MSH6 (Table 1). The 49 patients included 27 females and 22 males and 
summary clinic-pathologic data is shown in Table 1. Twenty-eight (55%) tumors 
belonged to patients presenting a germline mutation in MLH1, 22 (43%) in MSH2, and 
one (2%) in MSH6. Thirty-three of these families fulfilled the Amsterdam criteria, 
whereas the remaining presented the Bethesda criteria for genetic testing (Table 1). 
 
MMR immunohistochemical analysis 
For the assessment of MLH1, MSH2, MSH6 and PMS2 immunoexpression, four µm 
sections were cut and placed in silanyzed slides. Immunostaining was performed 
using an avidin-biotin complex peroxidase method (Elite PK-6200, Vector, 
Burlingame, CA, USA). Briefly, after dewaxing the sections, endogenous peroxidase 
activity was inhibited with freshly prepared 0.5% hydrogen peroxide in distilled water 
for 20 min. Antigen retrieval was performed with EDTA buffer, pH8, for 40 minutes. 
Incubation with primary antibodies for MLH1 (Clone G168-15, BD Pharmingem, San 
Jose, CA, USA), MSH2 (Clone G219-1129, BD Pharmingem), MSH6 (Clone 44, BD 
Pharmingem) and PMS2 (Clone A16-4, Zytomed Systems, Berlin, Germany) was 
performed overnight at 4ºC, at dilutions 1:100, 1:300, 1:1000,  and 1:50, respectively, 
in 1% BSA in phosphate buffer saline (PBS). All incubations were performed in a 
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humified chamber. Sections were developed with a peroxidase substrate solution 
(0.05% 3,3-diaminobenzidine tetrahydrocloride, 0.01% H2O2 in PBS), counterstained 
with hematoxylin, dehydrated and mounted. Appropriate positive and negative 
controls were used for each antibody. Assessment of MLH1, MSH2, MSH6 and 
PMS2 immunoexpression was performed by light microscopy at x400 magnification.  
 
Microsatellite instability analysis 
Microsatellite instability evaluation was performed using the Bethesda panel of 
markers (BAT25, BAT26, D2S123, D5S346 and D17S250) and the 1997 National Cancer 
Institute guidelines. PCR was carried out as previously described using fluorescence-labeled 
primers (Dietmaier et al, 1997). Fragments were analyzed for length variations on an ABI 
Prism 310 DNA sequencer (Applied Biosystems, Foster City, USA) and allele sizes were 
determined using the Genemapper software (version 3.7, Applied Biosystems). The results 
were independently scored by two observers and an additional round of analyses confirmed 
the results. 
 
Target gene analyses 
For somatic mutation analysis, we selected 17 genes belonging to pathways 
involved in CRC carcinogenesis and most of them known to present mutations in 
coding microsatellite sequences in tumors with MSI: TGFBR2 (A)10, ACVR2A (A)8, 
BMPR1A (T)6 (two sequences), BMPR2 (A7) and (A)11, EGFR (A)13, E2F4 
(CAG)13, BAX (G)8, PRDM2 (A)8 and (A)9, TCF7L2 (A)9, APC (A)6 and (A4), AXIN1 
(C)6 (two sequences) and (G)6, AXIN2 (A)6, (G7), (C)5 (two sequences) and (C)6, 
PTEN (A)6 (two sequences), MSH6 (C)8, MSH3 (A)8, IGF2R (G)8, and B2M (CT)4 
(Supplementary Table 1). BMPR1A, BMPR2, PTEN, PRDM2, APC, AXIN1 and 
AXIN2 each include two or more repeat sequences. Selected microsatellite 
sequences of the potential target genes were analyzed by PCR and fragment 
analysis, except AXIN2. PCR was carried out as previously described using the 
fluorescence-labeled primers presented in Supplementary Table 1 (Dietmaier et al, 
1997; Oliveira et al, 1998). Fragments were analyzed for length variations on an ABI 
Prism 310 DNA sequencer and allele sizes were determined using Genemapper 
68 
 
PAPER III 
software. The results were independently scored by two observers and an additional 
round of analyses confirmed the results. Additionally, all cases that presented length 
variations between tumor and matching blood samples were confirmed by direct 
sequencing on an ABI 310 DNA sequencer using Big Dye Terminator V1.1 Chemistry 
(Applied Biosystems), according to the manufacturer’s recommendations. AXIN2 
microsatellite sequences were analyzed by direct sequencing. 
 
Statistical analysis 
Statistical analysis was carried out with SPSS version 22. Results were expressed in 
absolute frequencies and percentages. The statistical significance of association 
between different variables was performed using the Fisher Exact Probability Test. 
Analysis of variance (ANOVA) was performed to compare group means and the 
statistical significance among the samples was assessed using the Scheffe Multiple 
comparison test. P values inferior to 0.05 were considered statistically significant. 
 
RESULTS 
MMR immunohistochemical analyses 
All tumors from the Porto test series analyzed by immunohistochemistry from 
patients presenting a mutation in MLH1 gene showed absence of MLH1 and PMS2 
protein expression; patients with a MSH2 mutation showed absence of MSH2 and 
MSH6 protein expression; patients with a mutation in MSH6 gene showed absence of 
MSH6 protein expression and one also presented loss of MSH2 protein expression; 
and the tumor of the patient with the PMS2 mutation showed loss of PMS2 protein 
expression. In the additional series from Basel, all the CRC analyzed by 
immunohistochemistry from patients presenting a mutation in MLH1 gene showed 
absence of MLH1, patients with a MSH2 mutation showed absence of MSH2 protein 
expression and patients with a mutation in MSH6 gene showed absence of MSH6 
protein. 
 
Overall microsatellite instability  
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The frequency of MSI in the test series from Porto was 99% (77/78) and the 
only CRC that did not present MSI belonged to a patient carrying a germline mutation 
in the MSH6 gene. In the additional series from Basel all 51 Lynch syndrome CRC 
presented MSI.   
 
Target gene mutation frequencies 
The microsatellite sequence most frequently mutated in the test series from 
Porto was ACVR2A (90.9%), followed by TGFBR2 (89.6%), EGFR (88.3%) and 
BMPR2 (A)11 sequence (74%). Mutations in the E2F4 (51.9%), MSH3 (49.4%), BAX 
(44.2%), TCF4 (41.6%), and BMPR2 (A)7 microsatellite sequence (35.1%) were also 
frequent. The remaining genes presented a mutational frequency inferior to 30% 
(Table 2). All the MSI CRC presented microsatellite instability in at least one of the 
genes analyzed and the overall mean of mutation frequency was 6.7±2.4.  
In the additional series from Basel we only analyzed the target gene 
sequences showing significant differences between proximal and distal CRC (see 
below), namely the MSH3 (A)8 and BMPR2 (A)7 microsatellite sequences. The 
mutational frequency in this series was 47.1% and 39.2% for MSH3 and BMPR2, 
respectively, being 48.4% for MSH3 and 36.7% for BMPR2 in the total series. 
 
Target gene analysis by germline MMR mutation 
The mean frequency of target gene mutations was 7.1±2.1 in the tumors from 
patients presenting a germline mutation in MSH2, 6.8±2.5 in MLH1 carriers, 3.0±1.6 
in MSH6 carriers, and the single tumor from a PMS2 carrier had 7 mutations. In order 
to examine whether there were statistically significant differences among these 
groups a one-way ANOVA was conducted. The results revealed statistically 
significant differences among the groups (P=0.001). Post-hoc Scheffe tests revealed 
statistically significant differences between MLH1 and MSH6 (P=0.003), MSH2 and 
MSH6 (P= 0.001) but not between MLH1 and MSH2 (P=0.884) (Figure 1A).  
No association was observed between the target gene mutational frequencies 
and pattern according to the germline mutated gene and the type of mutation, nor 
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when comparing founder mutations to other mutations in the same gene and CRC 
from the same individual.  
 
Target gene analysis by somatic MMR mutation 
CRC presenting somatic mutations in MSH3 and/or MSH6 harbored a higher 
mean frequency of mutations in the other microsatellite sequences analyzed when 
compared to the CRC without somatic mutations is these two MMR genes. The mean 
mutational frequency was 7.4±1.7 in the tumors presenting only somatic MSH3 
mutations, 7.4±2.2 when only MSH6 was mutated, 9.4±1.2 when both MSH3 and 
MSH6 were mutated, and 5.0±2.0 when no MSH3/MSH6 somatic mutation was 
present. The differences were statistically significant among the groups (P<0.001), 
and the Post-hoc Scheffe test revealed a statistically significant difference between all 
the groups presenting somatic mutations in MSH3 and/or MSH6 and the group of 
tumors without any of these mutations (P<0.05) (Figure 1B). 
 
Target gene mutation analysis by tumor location 
The mean frequency of target gene mutations in proximal and distal colon 
tumors was 6.33±2.3 and 7.42±2.4, respectively, being this difference not statistically 
significant. When considering tumor location, two microsatellite sequences were 
preferentially mutated in tumors with origin in the distal colon (Table 2). In the CRC 
test series from Porto, BMPR2 (A)7 microsatellite sequence and MSH3 mutations 
were present in 14 (53.8%) and 18 (69.2%) out of 26 MSI distal carcinomas, whereas 
in MSI proximal carcinomas mutations were present in 13 (25.5%) and 20 (39.2%) out 
of 51 tumors, the difference being statistically significant (P=0.022 for BMPR2 and 
P=0.017 for MSH3) (Table 2). This result was confirmed when we enlarged the series 
with the group of CRC from Lynch syndrome patients from Basel (P=0.039 for MSH3 
and P=0.012 for BMPR2) (Figure 2). Other genes show different mutation frequencies 
according to the large bowel site of origin (Table 2), but their lower mutation 
frequencies require much large tumor series to evaluate their significance. For 
instance, APC microsatellite mutations were only detected in the proximal colon, 
whereas AXIN1, AXIN2, and PTEN microsatellite mutations only rarely were found in 
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the proximal CRC and were recurrently detected in distal CRC. No association was 
observed between target genes mutational pattern or frequency with other clinic-
pathological features, namely gender, mean age of CRC diagnosis, tumor staging or 
differentiation grade. 
 
DISCUSSION  
CRC in Lynch syndrome patients present certain clinicohistopathologic 
features that differentiate them from MSI sporadic CRC, namely a younger age at 
diagnosis and the more frequent presence of lymphocytic infiltration and a mucinous 
histologic type (Young et al, 2001; Shia et al, 2003; Yearsley et al, 2006). 
Furthermore, although Lynch syndrome CRC with MSI tend to occur more frequently 
in the proximal colon, some authors have reported frequencies up to 40% of MSI 
distal carcinomas in Lynch syndrome patients, contrasting with sporadic MSI cancers 
that occur in the proximal colon in ~90% of the cases (Kim et al, 1994; Mueller-Koch 
et al, 2005; Moghbeli et al 2011; Moussa et al, 2011). The frequency of proximal and 
distal CRC in the overall series of MMR mutation carriers we here present is 67% and 
33%, respectively, which confirms that a noteworthy proportion of CRC in Lynch 
syndrome patients occurs in distal colon. Irrespective of tumor location, it is thought 
that MSI is a hallmark of CRC in Lynch syndrome patients, occurring in more than 
95% of the tumors (Aaltonen et al, 1994; Dietmaier et al, 1997). The frequency of 
microsatellite instability in the test series from Porto was 99% of the 78 CRC, with 
only one tumor without MSI belonging to a patient carrying a germline mutation in 
MSH6, and in the Basel additional series all 51 tumors presented MSI. Since a 
somewhat lower frequency of MSI has been described for MSH6 germline carriers 
(Peterlongo et al, 2003; Barnetson et al, 2006), the series we here present are 
representative of Lynch syndrome CRC.  
There is a well-established association between an ineffective MMR system 
and mutations in genes with key cellular roles in CRC of Lynch syndrome patients. 
Furthermore, it has been demonstrated that mutational inactivation of specific target 
genes and pathways provide a growth advantage to affected cells (Furlan et al, 
2002). With the purpose of comparing the mutation pattern of target genes in MSI 
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CRC from Lynch syndrome patients stratified by tumor location and germline mutation 
type, we initially analyzed 78 tumors for microsatellite instability in genes predicted to 
be selective target genes of MSI and known to be involved in several pathways of 
colorectal carcinogenesis, especially the TGFβ superfamily and WNT pathways. All 
candidate genes except BMPR1A presented frameshift mutations in the microsatellite 
sequences analyzed, with a frequency that ranged from 2.6% (AXIN1) to 90.9% 
(ACVR2A). All MSI CRC cases presented at least one mutation in the genes 
analyzed and the overall mean mutation frequency was 6.7±2.4. We also observed 
that CRC from patients with a germline mutation in MSH6 presented a significantly 
lower frequency of target gene mutations when compared to the groups with MLH1 or 
MSH2 germline mutations. Wu et al (1999) had already suggested that MSH6 may be 
involved in a proportion of Lynch syndrome patients presenting MSI-low tumors. More 
recently, Laghi et al (2012) also observed that the mutational rate in specific target 
genes was significantly lower in MSH6 than in MLH1 and MSH2 deficient tumors. 
A considerable frequency of somatic mutations in MSH3 and MSH6 
microsatellite sequences have been described in CRC from patients with germline 
mutations in MMR genes (Akiyama et al, 1997; Yamamoto et al, 1998). These 
mutations are considered as secondary events resulting from a germline MMR gene 
deficiency and are defined as "secondary" mutators in a "mutator that mutates 
another mutator" model (Akiyama et al, 1997; Yamamoto et al, 1998). In our study, 
mutations in the MSH3 and MSH6 mononucleotide repeats were detected in 49.4% 
and 24.7% of the CRC analyzed, respectively. According to the literature, their 
mutational frequency in Lynch syndrome CRC with MSI is 52 to 58.3% for MSH3 and 
16.7 to 34% for MSH6 (Akiyama et al, 1997; Yamamoto et al, 1998; Miyaki et al, 
2001). We observed that CRC with somatic mutations in MSH3 and/or MSH6 
presented a higher mean frequency of mutations in the other microsatellite 
sequences analysed when compared to CRC without somatic mutations is these two 
MMR genes. These could indicate that mutations in two or more MMR genes may 
enhance MSI and hence the accumulation of mutations in other cancer associated 
genes during tumor progression (Akiyama et al, 1997; Yamamoto et al, 1998; Laghi et 
al, 2012). Interestingly, we observed that the MSH3 gene was significantly more 
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frequently mutated in Lynch syndrome tumors with origin in distal colon. This 
association was confirmed when we enlarged the initial test series with the additional 
series from Basel, indicating that this gene is preferentially involved in the 
development or progression of distal colon cancer in Lynch syndrome patients. 
The most frequently mutated genes belonged to the TGFβ superfamily of 
proteins, which includes the TGFβ, activin and BMP subfamilies. It plays a critical role 
in carcinogenesis via regulation of cell growth, differentiation, proliferation, and 
apoptosis and it is estimated that ~80% of human colorectal cancers harbor mutations 
affecting at least one component of TGFβ superfamily signaling (Grady et al, 1999; 
Blobe et al, 2000). TGFBR2 and ACVR2A have been described as frequently 
mutated in MSI cancers, namely in Lynch MMR deficient tumors (Fujiwara et al, 1998; 
Miyaki et al, 2001). In our series these two genes were the most frequently mutated 
supporting the idea that alterations in these genes are important for the development 
of MSI CRC in the context of Lynch syndrome. On the other hand, the involvement of 
the BMP pathway in MSI CRC has scarcely been studied (Kodach et al, 2008). The 
BMP pathway has been implicated in the initiation of colorectal cancer among 
individuals with juvenile polyposis harboring BMPR1A mutations. BMP signaling is 
mediated by its receptors (BMPR1 and BMPR2) and downstream molecules such as 
Smad. In this study, we observed a high frequency of mutations in the microsatellite 
sequences of BMPR2 (74% and 35.1% in (A)11 and (A)7, respectively). Kodach et al 
(2008) also found a high mutational frequency (81.4%) in the (A)11 microsatellite 
sequence in sporadic MMR deficient tumors and indicated that loss of BMPR2 
expression is associated with microsatellite instability in this sequence. Regarding the 
(A)7 microsatellite sequence, they detected instability in two MSI cell lines and none 
in the MMR-deficient tumors, whereas none of the MSS cell lines and MMR proficient 
tumors analyzed presented mutations in either microsatellite sequences (Kodach et 
al, 2008). Furthermore, Park et al (2010) detected mutations in BMPR2 (A)7 
sequence in 13.2% of sporadic CRC associated with loss of BMPR2 expression. 
Further studies are needed to clarify the role of the (A)7 tract mutations in BMPR2 
function and expression, given that almost all cases presented in concomitance 
alterations in the more commonly mutated (A)11 tract. Kodach et al (2008) also 
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observed that alterations in BMPR2 occurred in concomitance with TGFBR2 and 
ACVR2 mutations, suggesting that loss of one of these receptors is insufficient for 
complete pathway disruption. On the other hand, some of these microsatellite 
mutations may be bystander events that do not play a causal role in carcinogenesis. 
We also observed that the BMPR2 (A)7 microsatellite sequence presented a 
statistically significant higher mutational frequency in distal Lynch syndrome CRC 
when compared to proximal CRC. This association was confirmed when we enlarged 
the test series with the additional Lynch syndrome series from Basel, suggesting that 
mutation at the (A)7 microsatellite sequence of BMPR2 might confer higher selective 
advantage in distal CRC carcinogenesis in Lynch syndrome patients. 
Some studies indicate that alterations in the WNT pathway may play an 
important role in the tumorigenesis of MMR deficiency tumors (Miyaki et al, 1999; 
Huang et al, 2004; Thorstensen et al, 2005). WNT signaling plays an important role in 
normal embryonic development of different tissues and regulates a variety of cellular 
functions including differentiation, growth, and apoptosis. We detected a low 
frequency of mutations in APC, AXIN1, AXIN2 and PTEN, but a high frequency in 
TCF7L2. Mutations in the A9 repeat in the TCF7L2 gene have been reported with a 
high frequency (33% to 58%) in Lynch syndrome CRC (Zhou et al, 2002; Yamaguchi 
et al, 2006). Although some studies indicate TCF7L2 as a true target gene in 
colorectal carcinogenesis, others demonstrated by functional studies that mutations in 
the TCF7L2 microsatellite sequence had no significant effect (Duval et al 1999; 
Ruckert et al, 2002). Further studies are needed to understand if alterations in this 
microsatellite sequence contribute to colorectal carcinogenesis or are only passenger 
mutations. 
Recently, mutations in a polymorphic (A)13/14 repeat within the 3’UTR of 
EGFR were described in a high percentage (59 to 81%) of sporadic MSI colon 
cancers (Yuan et al, 2009; Deqin et al, 2013; Sarafan-Vasseur et al, 2013). Although 
one study demonstrated that these mutations result in increased EGFR expression 
through enhanced EGFR mRNA stability, the other did not observe EGFR mRNA 
increase (Yuan et al, 2009; Sarafan-Vasseur et al, 2013). To best of our knowledge, 
the presence of microsatellite instability in this sequence has not been studied in 
75 
 
PAPER III 
 
Lynch syndrome CRC before. We observed a higher frequency of mutations (88.3%) 
in Lynch syndrome CRC than what has been observed in sporadic MSI CRC. Such a 
high mutation frequency is an indicator of selective advantage, but additional 
functional studies are needed to clarify if EGFR is a true target gene in the MSI 
pathway of colorectal carcinogenesis, especially in the context of Lynch syndrome.  
Genes involved in cell cycle control and apoptosis were also found to be 
frequently mutated in Lynch syndrome CRC, namely E2F4, BAX and PRDM2 genes. 
Our mutational frequency is in accordance with that detected by other studies, 
indicating that these are target genes of genetic instability in Lynch syndrome CRC 
(Sakao et al, 1998; Fujiwara et al, 1998; Yagi et al, 1998; Chadwick et al, 2000; 
Miyaki et al, 2001; Moriyama et al, 2002; Yamaguchi et al, 2006). Furthermore, we 
also detected mutations in the IGF2R and B2M genes. IGF2R participates in the 
signal transduction of TGFβ and is found to be mutated in ~24% of Lynch syndrome 
CRC with MSI and mutations in B2M gene represent an important mechanism of 
immune evasion in MSI colon carcinogenesis (Miyaki et al, 2001; Bicknell et al, 1996). 
As mentioned above, we observed that mutations in microsatellite sequences 
(A)7 of BMPR2 and (A)8 of MSH3  were significantly more frequent in CRC with origin 
in distal colon. Interestingly, the results concerning MSH3 are different from the ones 
we observed in a previous study of MSI sporadic tumors, where alterations in MSH3 
were very rare in tumors of distal colon (Pinheiro et al, 2010). Furthermore, the 
significantly lower frequency of TGFBR2 mutations we previously observed in 
sporadic MSI CRC (Pinheiro et al, 2010) was not seen in the present study with 
Lynch syndrome patients (Figure 3). Qualitative (type of target gene) and quantitative 
(number and frequency of altered target genes) differences have been observed 
regarding MSI target genes in different types of cancers. For instance, significant 
differences have been described between the MSI profiles of endometrial and 
colorectal cancers from Lynch syndrome patients presenting the same germline 
mutation. Somatic mutations in TCF7L2 were observed in ~47% of Lynch syndrome 
CRC, but not in endometrial cancers (Planck et al, 2000). Similarly, TGFBR2 
mutational frequency is higher in MSI colon carcinomas (70 to 90%) than in MSI 
endometrial carcinoma (17 to 19%), whereas PTEN instability was observed more 
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frequently (~20%) in endometrial carcinomas as compared to MSI CRC (~5%), 
suggesting that biological features and functional roles of target genes may differ 
depending on the tissue of tumor origin (Lu et al, 1995; Myeroff et al, 1995; Fujiwara 
et al, 1998; Duval et al, 1999, Kuismanen et al, 2002). Our data suggest that target 
genes differ in colorectal carcinomas depending on large bowel site of origin and 
between Lynch syndrome and sporadic MSI CRC, suggesting that carcinogenesis 
can occur by different routes even if driven by generalized MSI (Dierssen et al, 2007). 
Significant differences in the spectrum of molecular alterations between MSI Lynch 
syndrome and sporadic CRC have been observed. BRAF mutations, namely the 
p.Val600Glu, have been identified in sporadic MSI CRC associated with MLH1 
promoter hypermethylation, but not in Lynch syndrome CCR (Wang et al, 2003; 
Domingo et al, 2004). Conversely, CTNNB1 gene mutations are frequent (43%) in 
Lynch syndrome tumors but not in sporadic MSI CRC (Miyaki et al, 1999; Johnson et 
al, 2005). The differences in the molecular profiles of the two pathways are consistent 
with the differing carcinogenesis routes of hereditary versus sporadic MSI CRC, 
specifically the traditional adenoma-carcinoma sequence in the former and a serrated 
route in the latter (Jass, 2007). Furthermore, the different embryological origin or 
proximal and distal bowel may contribute to the molecular heterogeneity of MSI CRC, 
similarly to what happens in carcinogenesis of different organs in Lynch syndrome 
patients. 
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FIGURES 
 
Figure 1 - (A) Box plot analyses of the mean frequency of target gene mutations (Y 
axis) in CRC samples from the test series categorized by MMR germline mutation (X 
axis). (B) Box plot analyses of the mean frequency of target gene mutations (Y axis) 
in CRC samples from the test series categorized by MMR somatic mutation status (X 
axis). The mean comparison was calculated using the One-way ANOVA test. 
Statistical significance among the samples was assessed using the Scheffe Multiple 
Comparison Test.  
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Figure 2 - Mutational frequency of the microsatellite sequences (A)7 of BMPR2 and 
(A)8 of MSH3 genes according to tumor location in tumors from both series of Lynch 
syndrome patients. 
 
 
Figure 3 - Mutational frequency in TGFBR2 (A)10 and MSH3 (A)8 microsatellite 
sequences categorized by tumor location in sporadic (Pinheiro et al, 2010) and Lynch 
syndrome MSI CRC (present report).  
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Table 1 – Clinicopathologic characteristics of the Lynch syndrome patients and families. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Information was not available for 12 and 5 CRC from the Portuguese and Swiss Lynch syndrome families, respectively. 
b Information was not available for 19 and 13 CRC from the Portuguese and Swiss Lynch syndrome families, respectively. 
na - not available 
 Portuguese Lynch syndrome families Basel Lynch syndrome families 
 Total MLH1 MSH2 MSH6 PMS2 Total MLH1 MSH2 MSH6 
Families 50 16 (31%) 27 (55%) 6 (12%) 1 (2%) 48 26 (54%) 21 (44%) 1 (2%) 
          
Criteria          
Amsterdam 28 (56%) 9 (32%) 18 (64%) 1 (4%) 0 (0%) 33 (69%) 22 (67%) 10 (30%) 1 (3%) 
Bethesda 22 (44%) 7 (32%) 9 (41%) 5 (23%) 1 (5%) 15 (31%) 4 (27%) 11 (73%) 0 (0%) 
          
Nº CRC patients 65 25 (39%) 33 (51%) 6 (9%) 1 (2%) 49 27 (55%) 21 (43 %) 1 (2%) 
          
Gender          
Female  32 (49%) 13 (41%) 16 (50%) 2 (6%) 1 (3%) 27 (55%) 15 (56%) 11 (41%) 1 (4%) 
Male  33 (51%) 12 (36%) 17 (52%) 4 (12%) 0 (0%) 22 (45%) 12 (55%) 10 (45%) 0 (0%) 
          
CRC diagnosis age (years)          
Mean 46 46 46 44 55      na      na      na      na 
Range 15-75 27-68 15-75 21-71       na      na      na      na 
≤50 55 (71%) 21 (38%) 29 (53%) 5(9%) 0 (0%)      na      na      na      na 
>50 23 (29%) 10 (43%) 11 (48%) 1 (4%) 1 (4%)      na      na      na      na 
          
Total  CRC  78 31 (40%) 40 (51%) 6 (8%) 1 (1%) 51 28 (55%) 22 (43%) 1 (2%) 
          
CRC localization          
Proximal 51 (65%) 23 (45%) 24 (47%) 4 (8%) 0 (0%) 35 (69%) 22 (63%) 12 (34%) 1 (3%) 
Distal 27 (35%) 8 (30%) 16 (59%) 2 (7%) 1 (4%) 16 (31%) 6 (38%) 10 (63%) 0 (0%) 
          
TNM stagea          
I/II 45 (68%) 20 (44%) 23 (51%) 2 (4%)       - 32 (70%) 20 (63%) 12 (38%) 0 (0%) 
III/IV 21 (32%) 9 (43%) 9 (43%) 3 (15%)       - 14 (30%) 6 (43%) 7 (50%) 1 (7%) 
          
Differentiation gradeb          
well/moderately 53 (90%) 20 (38%) 28 (53%) 5 (9%) 0 (0%) 25 (66%) 15 (60 %) 10 (40 %) 0 (0%) 
Poorly 6 (10%) 2 (33%) 3 (50%) 0 (0%) 1 (17%) 13 (34%) 9 (69%) 4 (31%) 0 (0%) 
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Table 2 – Test series mutational frequency of the target genes microsatellite sequence 
according to tumor location. 
 
 
 
 
 
 
 
 
  
 
 
Gene 
Total 
(%) 
Proximal colon 
(%) 
Distal colon 
(%) P 
ACVR2 90.9 90.2 92.3  
TGFBR2 89.6 90.2 88.5  
EGFR 88.3 88.0 92.3  
BMPR2 (A)11  74.0 72.0 80.8  
E2F4 51.9 60.0 40.0  
MSH3 49.4 39.2 69.2 0.017 
BAX 44.2 41.2 50.0  
TCF7L2  41.6 37.3 50.0  
BMPR2 (A)7  35.1 25.5 53.8 0.022 
RIZ  29.9 31.4 26.9  
MSH6 24.7 19.6 34.6  
IGFR2R 20.8 17.6 26.9  
B2M 9.1 11.8 3.8  
APC  7.8 11.8 0.0  
PTEN  7.8 2.0 19.2  
AXIN1  2.6 0.0 7.7  
AXIN2 3.9 2.0 7.7  
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Supplementary table 1 - Target gene microsatellite sequences and primer sequences. 
Target gene 
(mRNA Refseq) 
Chromossome 
location 
Function/Pathway Microsatellite 
sequence 
Exon (nucleotide position) Primer sequencea 
TGFBR2 
(NM_001024847.2) 
3p22 Growth factor receptor 
/TGFB 
(A)10  
 
exon 4 (c.449 to c.458) F - AGATGCTGCCTTCCTCCAAAGTGC 
R - GTTTCTTTTGCACTCATCAGAGCTACAGG 
ACVR2A 
(NM_001278579.1) 
2q22.3 
 
Growth factor receptor 
/TGFB 
(A)8  
 
exon 4 (c.278 to c.285) F - GTTGCCATTTGAGGAGGAAA 
R - GTTTCTTCAGCATGTTTCTGCCAATAATC 
BMPR1A 
(NM_004329.2) 
10q22.3 Growth factor receptor/ 
TGFB/BMP 
(T)6  
 
(T)6 
 
exon 4 (c.171 to c.176) 
 
exon 7 (c.436 to c.441) 
F - ATGCTTCATGGCACTGGGAT 
R - GTTTCTTAAGGCTTTTTGGCTTTCTGGA 
F - GCCGAGAAAAGTCGGAGCAT 
R - GTTTCTTGAGCAAAACCAGCCATCGAA 
BMPR2 
(NM_001204.6) 
2q33-q34 Growth factor receptor/ 
TGFB/BMP 
(A)11  
 
(A)7  
 
3’ UTR (c.*2891 to c.*2901) 
 
exon 12 (c.1742 to c.1748) 
F - ACCAGAATTAGGTCACTGAAAGA 
R - GTTTCTTGCTCATATGGTTGCTCTGAGGT 
F - TCCATCATACTGACAGCATCG 
R - GTTTCTTTGTGGTGTTTGTGGTTGTTG 
EGFR 
(NM_005228.3) 
7p12 Growth factor receptor/ 
MAPK, Akt and JNK 
(A)13b 
 
3’ UTR (c.*282 to c.*294) F - GCAAGAATATTGTCCCTTTGAGCA 
R - GTTTCTTTTCCTTGTTGGAAGAGCCCA 
E2F4 
(NM_001950.3) 
16q21-q22 transcription factor/ 
cell cycle 
(CAG)13b  
 
exon 7 (c.918 to c.956) F - CAACAACACTGGACACCCGGC 
R - GTTTCTTTCAAAGGAGGTAGAAGGGTTGG 
BAX 
(NM_004324.3) 
19q13.3-q13.4 Proapoptotic factor/ 
Apoptosis 
(G)8 
 
exon 3 (c.114 to c.121) F - ATCCAGGATCGAGCAGGGCG 
R - GTTTCTTACTCGCTCAGCTTCTTGGTG 
PRDM2 (RIZ) 
(NM_012231.4) 
 
1p36.21 transcription factor/ 
cell cycle 
(A)8  
 
(A)9 
 
exon 8 (c.4270 to c.4277) 
 
exon 8 (c.4459 to c.4467) 
F - GGACAGCCCAAAAGGCTTA 
R - GTTTCTTTTCAAGTCGGCCTTCTGC 
F - GAATAAACACGCCGCCTTCA 
R - GTTTCTTGATGAGTGTCCACCTTTCTTAGATGA 
TCF7L2  
(NM_001146274.1) 
10q25.3 transcription factor/ 
WNT signalling 
(A)9  
 
exon 14 (c.1395 to c.1403) F - GGGCACTGTGAAGTAAGCGA 
R - ATCTGAAGAGGGTGGGCTGA 
APC  
(NM_000038.5) 
5q21-q22 tumor suppressor 
WNT signalling 
(A)6  
(A)4 
exon 16 (c.4661 to c.4666) 
exon 16 (c.4679 to c.4682) 
F - CTGAGCCTCGATGAGCCATT 
R – GTTTCTTACGTGATGACTTTGTTGGCA 
aThe GTTTCTT “pig-tail” was added to the 5′ end of all reverse primers. 
b Polymorphic microsatellite sequence. 
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Supplementary table 1 (continued) 
 
Target gene 
(mRNA Refseq) 
Chromossome 
location 
Function/Pathway Microsatellite 
sequence 
Exon (nucleotide position) Primer sequencea 
AXIN1  
(NM_003502) 
16p13.3 WNT signaling  (C)6 
 
(C)6  
 
(G)6  
 
exon 2 (c.787 to c.792) 
 
exon 4 (c.1029 to c.1034) 
 
exon 6 (c.1518 to c.1523) 
F - ATCTGGATACCTGCCGACCT 
R - GTTTCTTCGTCGGACTCACCTGAACTC 
F - CCTCCTGCTCCTCTCTGAGT 
R - GTTTCTTATTGACCTGCACGCTCTCC 
F - TGGACGAGCACGTACAGC 
R - GTTTCTTTTCGCCCCTGACTTGGGTA 
AXIN2 
(NM_004655.3) 
17q23q24 
 
WNT signalling (A)6  
(G)7  
(C)5  
(C)6  
(C)5  
exon 8 (c.1920 to c.1925) 
exon 8 (c.1988 to c.1994) 
exon 8 (c.2007 to c.2011) 
exon 8 (c.2018 to c.2023) 
exon 8 (c.2128 to c.2132) 
F - AACCCAGTTTCTTTCCTTCT 
R - ATCCCTGCCTCAACCTA 
PTEN 
(NM_000314.4) 
10q23.3 tumor suppressor/ 
WNT signalling 
(A)6  
 
(A)6  
 
exon 7 (c.795 to c.800) 
 
exon 8 (c.963 to c.968) 
F - CTTTGAGTTCCCTCAGCCGT 
R - GTTTCTTTCACCAATGCCAGAGTAAGCA 
F - GAGCGTGCAGATAATGACA 
R - GTTTCTTCCCACAAAATGTTTAATTTAAC 
MSH6 
(NM_000179.2) 
2p16 Mismatch repair (C)8  
 
exon 5 (c.3254 to c.3261) F - GGGGTGATGGTCCTATGTGTC 
R - GTTTCTTTAGGCTTTGCCATTTTCCT 
MSH3 
(NM_002439.4) 
5q11-q12 Mismatch repair (A)8 
 
exon 7 (c.1141 to c.1148) F - ACCAGCTATCTTCTGTGCATCTC 
R - GTTTCTTAACATTTGTTCCTCACCTG 
IGF2R 
(NM_000876.2) 
6q26 Growth factor receptor 
 
(G)8  
 
exon 28 (c.3942 to c.3949) F - ACAGGTCTCCTGACTCAGAA 
R - GTTTCTTGCCGTCGGTACATGCTCAC 
B2M 
(NM_004048.2) 
15q21-q22.2 MHC class I (CT)4  
 
exon 1 (c.37 to c.44) F - CTGGCTTGGAGACAGGTGAC 
R - GTTTCTTGACTCACGCTGGATAGCCTC 
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The germline mutational spectrum of Lynch syndrome is highly heterogeneous 
considering the several types of mutations located throughout the four relevant MMR 
genes. However, specific mutations are observed at high frequencies in well-defined 
populations or ethnic groups, because of founder and or recurrent effects. The 
identification of founder mutations, besides increasing the cost-effectiveness of 
genetic testing of Lynch syndrome suspects, allows the analysis of mutation 
prevalence in different populations and mutation-specific effects on penetrance and 
disease phenotype (Chan et al, 2001; Wagner et al, 2003; Caluseriu et al, 2004; Sun 
et al, 2005). 
Additionally, molecular characterization of CRC arising in Lynch syndrome 
patients, namely the genes mutated somatically and the respective disrupted 
pathways, is imperative to increase our understanding of the carcinogenic 
mechanisms, which in turn might allow the discovery of potential treatment targets 
and/or predictive markers. 
 
1 - Identification of a novel exonic rearrangement affecting MLH1 
and the contiguous LRRFIP2 that is a founder mutation in 
Portuguese Lynch syndrome families  
 
Several studies have shown that large genomic rearrangements in MMR 
genes, mainly in MSH2 and MLH1, are a frequent cause of Lynch syndrome, 
reaching a proportion as high as 20% (Charbonnier  et al, 2002; Di Fiore et al, 2004;). 
Molecular characterization of large genomic rearrangements is essential to determine 
if it is a novel alteration and to understand the mutational mechanism responsible for 
its occurrence. The majority of studies with large rearrangement breakpoint 
identification propose that they are caused by homologous recombination between 
Alu elements (Moisio et al, 1996; Wang et al, 2003; Nyström et al, 1995).  
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We identified a novel MLH1 exonic rearrangement in 14 Portuguese Lynch 
syndrome families, accounting for ~17% of all Lynch syndrome families with 
pathogenic mutations identified at the Genetics Department of the Portuguese 
Oncology Institute of Porto at the time (data not shown). This rearrangement, 
detected by the Multiplex Ligation Probe Amplification (MLPA) methodology, 
comprised at least exons 17 to 19 of MLH1 gene and exon 26 of the contiguous 
LRRFIP2 gene. Breakpoint identification revealed that these families harbored an 
identical deletion involving MLH1 exons 17 to 19 and LRRFIP2 exons 26 to 29, 
corresponding to the mutation MLH1 c.1896+279_oLRRFIP2:c.1750-678del. Analysis 
of the genomic sequences flanking the deletion breakpoints suggested that this large 
rearrangement resulted from homologous recombination between two Alu sequences 
present in introns 16 and 25 of the genes MLH1 and LRRFIP2, respectively.  
All 14 families were originated from the Porto district countryside and haplotype 
analysis revealed a conserved region of ~1 Mb, indicating that these families share a 
common ancestor. Based on the mutation and recombination events observed in 
microsatellite haplotypes and assuming a generation time of 25 years, the age 
estimate for the MLH1 c.1896+279_oLRRFIP2:c.1750-678del mutation was 283±78 
years.  
 Founder mutations have been identified in Lynch syndrome families from 
several countries and population, namely China, the United States, Italy, and among 
Ashkenazi Jews (Chan et al, 2001; Wagner et al, 2003; Caluseriu et al, 2004; Sun et 
al, 2005). A well-known founder mutation is the deletion of MLH1 exon 16 that 
represents approximately 50% of all MLH1 mutations detected in Lynch syndrome 
families from Finland (Moisio et al, 1996). The identification of founder mutations 
facilitates the molecular diagnosis of Lynch syndrome by targeting the mutational 
analysis to specific gene regions before full screening of all MMR genes. Screening 
for the MLH1 c.1896+280_oLRRFIP2:c.1750-678del mutation as a first step may 
increase the cost-effectiveness of genetic testing of Lynch syndrome suspects of 
Portuguese ancestry, especially those originating from the north of Portugal. 
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2 - Identification of a MSH2 founder mutation in Portuguese Lynch 
syndrome families but recurrent worldwide 
 
The MSH2 c.388_389del mutation was detected in 16 Portuguese Lynch 
syndrome families, explaining 16% of our Lynch syndrome families with identified 
germline mutations at the time (data not shown). This germline mutation had already 
been reported in Lynch syndrome families from Germany, Scotland, England, and 
Argentina (Mangold et al, 2005; Barnetson et al, 2006; Naseem and Boylan et al, 
2006; Vaccaro et al, 2007). Due to the high frequency of the MSH2 c.388_389del 
mutation in our series and the various reports of its presence in other countries, we 
aimed to evaluate if this is a founder or a recurrent mutation. All the 16 known 
Portuguese families were originated from the north of Portugal and the informative 
families shared a haplotype of ~10 Mb, indicating that the MSH2 c.388_389del 
alteration is a founder mutation in Portugal with a relatively recent origin. The Lynch 
syndrome families with the MSH2 c.388_389del mutation living outside Portugal that 
we could study, showed no clear evidence for a common ancestry nor do they 
reported any Portuguese ancestry. The observed haplotypes suggested that the 
MSH2 c.388_389del mutation has occurred de novo in the background of different 
haplotypes worldwide, but shows a founder effect in Portugal. Haplotype analysis of 
various recurrent mutations demonstrated multiple origins and is in some cases 
associated with founder effects. For instance, the MSH2 splice-site mutation 
c.942+3A>T, which was proven to be widespread in the Newfoundland population 
through a founder effect, has been observed in many other populations arising de 
novo, and therefore is considered a worldwide recurrent mutation with a founder 
effect in Newfoundland (Froggat et al, 1999; Desai et al, 2000).  
Considering that this mutation appeared independently several times in the 
human genome, this region may be considered a hotspot within the MSH2 gene. 
Mutational hotspots, such as tandemly repeated sequences, can originate recurrent 
mutations and different mechanisms have been proposed for the generation of gene 
deletions mediated by short repeats and/or palindromes in the vicinity of the mutation. 
In the case of the recurrent MSH2 c.388_389del mutation we here report, a short 
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repeat motif (TCTCTCTC) exists immediately upstream of the deletion, so we 
hypothesize that a similar mechanism may be operative in its recurrent de novo origin 
(van der Luijt et al, 2001). 
As indicated previously, in populations where certain mutations are frequent, 
especially by a founder effect, important diagnostic implications exist. The high 
frequency of the MSH2 c.388_389del mutation in our Lynch syndrome families with 
identified germline mutations indicates that screening for this MSH2 mutation as a 
first step, together with the MLH1 founder mutation discussed above, may increase 
the cost-effectiveness of genetic testing of Lynch syndrome suspects of Portuguese 
ancestry, especially those originating from the north of Portugal, as the two mutation 
together account for a significant proportion of MMR mutations found in this region.  
 
3 - Target gene mutational spectrum in Lynch syndrome CRC 
according to MMR germline mutation 
 
The somatic molecular genetic marker associated with Lynch syndrome is MSI, 
occurring in more than 95% of the colorectal cancers arising in these patients due to 
MMR deficiency (Aaltonen et al, 1994; Dietmaier et al, 1997). Through this pathway, 
CRC progression is accelerated by a rapid mutation accumulation in coding repetitive 
sequences of target genes with growth-related functions (Perucho, 1996; Boland et 
al, 1998; Yamamoto et al, 1998; Yagi et al, 1998; Fujiwara et al, 1998; Calin et al, 
2000). 
We analyzed 78 Lynch syndrome CRC for MSI and mutations in genes 
predicted to be selective target genes of MSI and known to be involved in important 
pathways for colorectal carcinogenesis, especially the TGFβ superfamily and WNT 
pathways. Only one CRC did not present MSI (in the markers of the Bethesda panel 
and in any of the genes analyzed) and belonged to a patient with a germline mutation 
in the MSH6 gene. Additionally, we observed that CRC from patients with germline 
mutations in MSH6 presented a significantly lower frequency of target gene mutations 
when compared to the group with MLH1 or MSH2 germline mutations. According to 
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some authors, the microsatellite mutational rate in MSH6 deficient tumors is lower 
than in MLH1 and MSH2 genes (Wu et al, 1999; Laghi et al, 2012).  
A considerable frequency of somatic mutations was detected in the MSH3 and 
MSH6 microsatellite sequences. We also observed that CRC with somatic mutations 
in MSH3 and/or MSH6 presented a higher mean frequency of mutations in the other 
microsatellite sequences analyzed when compared to CRC without somatic mutations 
in these two MMR genes. Somatic mutations in microsatellite sequences in MMR 
genes are considered secondary events, since they result from a germline MMR gene 
deficiency and these somatically mutated genes are defined as "secondary" mutators 
in a "mutator that mutates another mutator" model. The additional inactivation of 
these genes may enhance MSI and hence the accumulation of mutations in other 
cancer-associated genes during tumor progression (Akiyama et al, 1997; Yamamoto 
et al, 1998; Laghi et al, 2012).  
The most frequently mutated genes belonged to the TGFβ superfamily of 
proteins, namely TGFBR2 and ACVR2A, supporting the idea that alterations in these 
genes are important for the development of MSI CRC in the context of Lynch 
syndrome (Fujiwara et al, 1998; Miyaki et al, 2001). We also observed a high 
frequency of mutations in the microsatellite sequences of BMPR2 gene that belongs 
to the BMP pathway. Regarding the WNT signaling pathway, we detected a low 
frequency of mutations in all genes except in TCF7L2. A high frequency of mutations 
was also detected in genes involved in cell cycle control and apoptosis, namely the 
E2F4, BAX and PRDM2 genes. To our knowledge, this is the first study that analyzed 
the presence of microsatellite instability in the (A)13/14 sequence of EGFR gene in 
Lynch syndrome CRC and a very high frequency of mutations was found.  
However, besides the differences related to the mean number of somatically 
mutated genes mentioned above, no significant association was seen regarding the 
mutational frequency and pattern of particular target genes with the germline mutated 
gene or the type of mutation, namely when comparing founder mutations to other 
mutations in the same gene. 
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4 - Target gene mutational spectrum in Lynch syndrome CRC 
according to large bowel location  
 
Multiple differences between cancer of the proximal and distal colon with 
regard to clinical behavior, epidemiological, pathological and molecular features 
suggest that the mechanisms of colorectal carcinogenesis may differ according to 
tumor location (Kapiteijn et al, 2001; Fernebro et al, 2002; Christie et al, 2012).  
We observed that mutations in microsatellite sequences (A)7 of BMPR2 and 
(A)8 of MSH3 were significantly more frequent in CRC with origin in distal colon. This 
association was confirmed when we enlarged the initial test series with the additional 
series from Basel, indicating that these two genes are preferentially involved in the 
development or progression of distal colon cancer in Lynch syndrome patients. 
Interestingly, the results concerning MSH3 are different from the ones we 
observed in a previous study of MSI sporadic tumors, where alterations in MSH3 
were very rare in tumors of distal colon (Pinheiro et al, 2010). Furthermore, the 
significantly lower frequency of TGFBR2 mutations we previously observed in 
sporadic MSI CRC (Pinheiro et al, 2010) was not seen in the present study with 
Lynch syndrome patients. Qualitative (type of target gene) and quantitative (number 
and frequency of altered target genes) differences have been observed regarding 
MSI target genes in different types of cancers. For instance, significant differences 
have been described between the MSI profiles of endometrial and colorectal cancers 
from Lynch syndrome patients presenting the same germline mutation regarding 
somatic mutations in TCF7L2, TGFBR2 and PTEN, suggesting that biological 
features and functional roles of target genes may differ depending on the tissue of 
tumor origin (Fujiwara et al, 1998; Duval et al, 1999; Planck et al, 2000; Zhou et al, 
2002; Kuismanen et al, 2002). Our data suggests that target genes differ in CRC 
depending on large bowel site of origin and between Lynch syndrome and sporadic 
MSI CRC, suggesting that carcinogenesis can occur by different routes even if driven 
by generalized MSI (Dierssen et al, 2007). Significant differences in the spectrum of 
molecular alterations between MSI Lynch syndrome and sporadic CRC have been 
observed. BRAF mutations, namely the p.Val600Glu, have been identified in sporadic 
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MSI CRC associated with MLH1 promoter hypermethylation, but not in Lynch 
syndrome CCR (Wang et al, 2003; Domingo et al, 2004). Conversely, CTNNB1 gene 
mutations are frequent (43%) in Lynch syndrome tumors but not in sporadic MSI CRC 
(Miyaki et al, 1999; Johnson et al, 2005). The differences in the molecular profiles of 
the two pathways are consistent with the differing carcinogenesis routes of hereditary 
versus sporadic MSI CRC, specifically the traditional adenoma-carcinoma sequence 
in the former and a serrated route in the latter (Jass, 2007). Furthermore, the different 
embryological origin or proximal and distal bowel may contribute to the molecular 
heterogeneity of MSI CRC, similarly to what happens in carcinogenesis of different 
organs in Lynch syndrome patients. 
 
101 
 
 102 
 
CONCLUSIONS 
CONCLUSIONS 
 
The main conclusions of this thesis are: 
1. The novel exonic rearrangement MLH1 c.1896+279_oLRRFIP2:c.1750-678del 
and the point mutation MSH2 c.388_389del mutation are two frequent 
Portuguese frequent founder mutations, the latter being a recurrent mutation 
worldwide. 
2. Screening for these two mutations as a first step may increase the cost-
effectiveness of genetic testing of Lynch syndrome suspects of Portuguese 
ancestry, especially those originating from the north of Portugal.  
3. Genes belonging to the TGFβ superfamily signaling pathways play an important 
role in the carcinogenesis of Lynch syndrome CRC, as they are the most 
frequently mutated. 
4. CRC from patients with germline mutations in MLH1 or MSH2 present a 
significantly higher frequency of target gene mutations when compared to 
patients with germline MSH6 mutations.  
5. CRC with somatic mutations in MSH3 and/or MSH6 present a higher mean 
frequency of mutations in the other genes with microsatellite sequences when 
compared to CRC without somatic mutations in these two MMR genes. 
6. Mutations in microsatellite sequences (A)7 of BMPR2 and (A)8 of MSH3 are 
significantly more frequent in CRC with origin in distal colon in Lynch syndrome 
patients. 
7. The pattern of genetic changes differs in colorectal carcinomas depending on the 
large bowel site of origin and between Lynch syndrome and sporadic MSI CRC, 
suggesting that carcinogenesis can occur by different pathways even if driven by 
generalized MSI.  
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Although MSI CRC are thought to be characterized by stable, near-diploid 
karyotypes, it is not known to what extent copy number neutral chromosomal 
changes, like those associated with uniparental disomy, are involved in colorectal 
carcinogenesis in Lynch syndrome patients and whether or not there are differences 
according to germline mutated gene or between proximal and distal colon. To 
address this issue, we will use the OncoScan™ FFPE Assay (Affymetrix, Santa 
Clara, USA) to simultaneously detect genome-wide copy number changes and allelic 
imbalances, as well as somatic point mutations in nine genes (BRAF, KRAS, EGFR, 
IDH1, IDH2, PTEN, PIK3CA, NRAS, TP53), in 46 CRC divided equally by proximal 
and distal colon location and belonging to patients with different types of MMR 
germline mutations.  
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